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Abstract:
This Master project addresses the poten-
tial application of polyvinylpyrrolidone-based
polymer micelles as a drug delivery system.
1 and 6 kDa polymer was used to form ei-
ther micelles loaded with curcumin as a model
hydrophobic drug, or to create empty mi-
celles by applying chloroform as a temporary
hydrophobic stabiliser. The physical prop-
erties of the synthesised micelles were stud-
ied using Nanoparticle Tracking Analysis to
determine the size distribution of the mi-
celles, and Atomic Force Microscopy to visu-
alize them. Glioblastoma (U87) and Fibrob-
last (CRL 2429) cell lines were used for in
vitro studies of the application of polymeric
micelles in drug delivery, with the main fo-
cus being on the mechanisms of drug uptake
in the cells as well as cytotoxicity. The cellu-
lar uptake of curcumin in micellar- and free
form was studied using Optical Fluorescent
Microscopy. Cytotoxicity assays were used to
determine the mortality of the cell lines, when
incubated with diﬀerent concentrations of mi-
cellar and free curcumin, as well as empty mi-
celles, for 24 hours. The studies of endocyto-
sis mechanisms were carried out using diﬀer-
ent endocytosis inhibitors including dynasore,
worthmaninn and sodium azide, followed by
either microscopic visualization of the cells or
cytometry measurements. Although no ﬁnal
conclusion was reached on the uptake mech-
anism, it was successfully demonstrated that
the micellar form of curcumin drastically en-
hances the uptake and eﬃcacy of the drug for-
mulation, as compared with the free form.
The contents of this report are freely available, but publication (with reference) is only
allowed with the consent of the authors.
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Abstrakt:
Dette speciale projekt omhandler potentielle anven-
delser af polyvinylpyrrolidone-baserede polymer mi-
celler som et drug delivery system. 1 og 6 kDa
polymer blev anvendt til at danne enten miceller
fyldt med curcumin som et karakteristisk hydro-
fobt lægemiddel; eller tomme miceller ved anven-
delse af kloroform, som en midlertidig hydrofob sta-
bilisator. De fysiske egenskaber af de syntetiserede
miceller blev undersøgt ved anvendelse af Nanopar-
ticle Tracking Analysis for at bestemme størrelses
fordelingen af micellerne og atomar kraft mikroskopi
til at visualisere dem. Glioblastoma (U87) og ﬁ-
broblast (CRL 2429) celle linjer blev anvendt til in
vitro undersøgelser i anvendelsen af polymer miceller
til drug delivery, med hovedfokus påmekanismerne
bag optagelsen af lægemidlet i cellerne, samt den
cytotoksiske eﬀekt. Den cellulære optagelse af cur-
cumin i micellær- og fri form blev undersøgt ved brug
af optisk ﬂuorescens mikroskopi. Cytotoksisk anal-
yse blev anvendt til at bestemme dødeligheden af
cellelinjerne, når de blev induceret med forskellige
koncentrationer af micellær- og fri curcumin, samt
tomme miceller i 24 timer. Undersøgelserne af en-
docytose mekanismer blev udført under anvendelse
af forskellige endocytose hæmningsstoﬀer, heriblandt
dynasore, worthmaninn og natriumazid, efterfulgt
af enten mikroskopisk visualisering af cellerne eller
cytometri målinger. Selvom ingen endelig konklu-
sion blev nået for optagelsesmekanismerne, blev der
med succes vist at den micellære form af curcumin
drastisk øger optagelsen og eﬀekten af lægemidlets
formulering sammenlignet med i den frie form.
Indholdet af denne rapport er frit tilgængelige, men oﬀentliggørelse (med henvisning) er
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1. Introduction
On a global scale, the spectrum of disease known as cancer is one of the most common causes
of death. In 2008 alone around 12 million patients were diagnosed with cancer, with 25 million
people already living with the disease and an estimate of 7 million cancer-related deaths. In the
future, the continuing growth of the worlds population coupled with longer lifespans will result
in these numbers only growing larger and are expected to almost double by 2030 according to
the International Agency for Research on Cancer (IARC).[1, 2]
Cancer is not a new disease. While it can be traced back hundreds of years, with the
earliest documented cases being found in Egyptian mummies [3, 4], it is only recently that our
understanding of it has improved enough for it to be treated. However, today the treatment of
cancer still remains one of the most challenging problems in medicine, and with the increasing
numbers of patients, the pressure for more advanced treatment methods is high. Some of the
current treatment methods are surgical intervention, radiation therapy and chemotherapy, but
they are not without concerns.[2, 5]
In 1996 Michael Baum hypothesised [6] that surgical removing of tumours could cause an
acceleration of tumour growth and metastatic growth, perhaps induced by the inﬂammatory
response during wound healing. These eﬀects may account for the poor survival beneﬁts, when
only a single method is used. This indicates that a second method to stop the continuing growth
of cancer cells is necessary. Chemotherapy is an essential secondary treatment, although its
eﬃciency is far from satisfactory. Traditional chemotherapy drugs are far from healthy towards
the patient, as they are toxic to healthy cells as well as cancer cell. These problems are mainly
caused by poor speciﬁcity in drug delivery, including problems with physiological barriers and
drug resistance.[2, 7]
In order to improve the treatment methods further, the development of new drug delivery
systems is driven by the demand to maximize the eﬀect of the medicine and minimize the
side eﬀects. Several drug carriers have been developed as potential carriers: liposomes, micro-
particles, nano-associates, nanoparticle, drug polymer-conjugates and polymeric micelles. A
promising method, which has been extensively studied in the past decade includes micelles
formed through self-assembly. They exhibit a number of properties, such as their small size
(<100 nm), their ability to solubilize hydrophobic drugs in their core, while the hydrophilic
corona interacts with the aqueous environments and forms hydrogen bonds. The hydrogen bonds
form a tight shell around the micelles and prevent protein adsorption and cellular adhesion.
This hydrophilic corona protects the micelles from the detection by the mononuclear phagocyte





Drug delivery systems (DDS) are methods or processes for administrating the introduction
of a therapeutic agent into the body. DDS can improve the therapeutic agent exposure and
eﬃcacy by controlling parameters such as the release rate, time and location in the body. DDS
processes include three concepts: the administration of the therapeutic product delivered to the
destination, the release of the active additive by the product and the transport of the active
additives across a biological membrane to the place of action.[10]
The DDS works as an integration between the patient and the therapy. It can be formed as a
device to deliver the therapy or it can be a way for the therapy to fulﬁl its purpose. Nonetheless,
it is of great importance to distinguish between the therapy and the device, since it is a criterion
for the administrative control of the DDS by the various medicine control agencies. When a
device loaded with a therapeutic agent is introduced in to a body, with the purpose of drug
administrating, it is considered a drug. If the device, on the contrary, is loaded with a drug, ifs
purpose is to prevent complications resulting from this device; it is then regulated as a device.
The spectra between the category of drug and device are very wide, making the allocation decide
on a cases to cases basis.[10]
1.1.1 Routes of delivery
A therapeutic drug can be administered into the human body by various anatomical routes. The
choice of delivery route depends on three factors: the disease, the product and the desired eﬀect.
Depending on the situation, the drug can be directly administrated into the aﬀected organ, or
given systemically, or be targeted to the aﬀected organ.[10, 11] There are various methods for a
systemic drug delivery by anatomical routes; these can be seen in table 1.1. Some of the most
frequent routes used for drug administration are oral and injections.
Table 1.1: A classiﬁcation of various systemic drug delivery methods by anatomical routes.










Transmucosal: buccal and through mucosa lining the rest of gastrointestinal tract
Transnasal




From a historical point of view, the oral route of drug administration is the oldest and most
applied route for novel and conventional drug delivery. The reasons for its preference are the
easy administration as well as the fact that the patients are more accepting towards it. However
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the oral route has various limitations, depending on the properties of the drug. The absorption
rate of drugs for systemic eﬀect can vary in a non-predictable way. High concentrations of acids
and digestive enzymes in the digestive tract can degrade drugs by making them unsolvable before
they reach the bloodstream. The oral route may not be suitable for drugs targeted to speciﬁc
organs. Several improvements have been implemented recently, in the formulation of drugs for
oral delivery, to preserve their action.[10, 11]
1.1.1.2 Delivery by parenteral
Parenteral administration is an essential part of the medical practice and is the most commonly
used invasive method of drug delivery. The parenteral route is the most eﬀective route for
delivering of active pharmaceutical substances with poor bioavailability and narrow therapeutic
index, into the body, because it bypasses the intestinal tract. There are various routes
of parenteral administration available, the most generally applied, include intramuscular,
intravenous, intra-arterial and subcutaneous routes.[10, 11, 12, 13]
Figure 1.1: The generally applied routes of parenteral administration. Taken from Ochoa et
al. [12].
The advantages of parenteral administration include rapid onset action and predictable and
rather complete bioavailability. Furthermore, it is a very reliable drug delivery route, especially
for patients that are comatose or too ill to ingest drugs orally. Patients that are bed ridden or
hospitalized can also become dependent on parenteral nutritions: such as ﬂuids, nutrients and
electrolytes and many of the important pharmaceuticals are only available in injection form.
Even with the many beneﬁts, there are some drawbacks to the parenteral delivery. Firstly
injection can be painful and uncomfortable for patient, which leads to complains. Secondly,
there is a risk of infection, allergic reactions and embolism, as well as hypersensitivity reactions.
Furthermore injection drugs are more expensive to manufacture, than conventional drugs since
it requires specialized equipment, devices and techniques to prepare.[10, 12, 13]
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1.1.2 Targeted drug delivery
Today the majority of applied pharmaceuticals will, upon ingestion/injection, be distributed
throughout the body. A drug is transported around the body through systemic circulation
without any speciﬁc direction, both upon ingestion and injection. In order for a drug to reach an
aﬀected site, it has to cross diﬀerent biological barriers, as well as organs, cells and intracellular
compartments. During this transportation, the drug can produce unwanted side eﬀects on
organs and tissues, or it can become inactivated. Therefore, in order to achieve the required
concentration of a drug at a given aﬀected site, it has to be administered in high quantities,
where a large part of it ends up in normal healthy tissue.[14, 15]
The wasted part of the administrated drug can in some situations, depending on the drug,
cause a lot of damage in the body, leading to unwanted and negative side eﬀects.[14] A classical
and common example of this is chemotherapy. Chemotherapy is used to treat diﬀerent types of
cancers by attacking the active cells. Cancer cells are active cells that are dividing and growing,
but the same can be said of many healthy cells, which are found in human blood, digestive system,
hair follicles and in the mouth. When chemotherapy drugs are being circulated throughout the
body in high quantities, they can cause side eﬀect by attacking healthy cells. These side eﬀects
diﬀer depending on the drug and the patient receiving them.[16]
In order for chemotherapy to be a clinically eﬀective form of treatment, the amount of drug
at the target site has to maintain a desired concentration level for a suﬃcient time. A region
of the body where this is especially diﬃcult, is in the brain. The blood-brain barrier (BBB)
prevents most therapeutic drugs from reaching the central nervous system (CNS) from the blood
circulation, making it extremely diﬃcult to deliver drugs to the brain.[17] 100% of large-molecule
drugs, e.g. peptides, gene therapies, monoclonal antibodies etc., do not penetrate the BBB;
this also applies to >98% of all small molecules. In the Comprehensive Medicinal Chemistry
database there are >7000 drugs, where only 5% can treat the CNS, and are limited to treatment
of depression, schizophrenia and insomnia.[18] There have been developed several brain drug
delivering approaches, such as intra-cerebral and intracerebroventricular administration, which
are highly invasive methods, as well as intranasal delivery, a non-invasive method. These
approaches are not commonly used, since they are risky, costly and not suitable for less localized
brain tumours.[17] Targeting nano-material objects, which behave as a unit in terms of transport
and properties, have been widely investigated for brain drug delivery. Nano-materials have been
found to internalize into cells, including the brain capillary endothelial cells by endocytosis and
transcytosis.[17]
Drug targeting could be the solution to all these problems. Drug targeting can be deﬁned
as a drugs ability to accumulate its active pharmaceutical ingredient (API) in a target area of
the body, independently of the method or site of administration. This would ideally lead to a
high concentration in the target area, while keeping the concentration in the non-target areas
below certain minimum levels, to prevent negative side eﬀects. Furthermore, drug targeting has
other noticeable advantages. The quantity of the API can be reduced greatly, together with
the cost of the therapy. The concentration of API at the target site, can be largely increased,
without causing side eﬀects in unrelated tissues. The administration protocols may furthermore
by simpliﬁed.[14, 15]
A conceptual version of a targeted pharmaceutical drug has to contain several diﬀerent
components: a pharmaceutical agent, a targeting moiety, a structure capable of carrying
molecules per targeted moiety to the target. Recognition of the target can occur on diﬀerent
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levels: organ, cellular or molecular. On the organ level, speciﬁc cells of a given organ are
targeted or individual components of the cells. The same can be stated for the molecular level,
since each organ or tissue has a unique component (antigens, proteins or fusion gene [19]) speciﬁc
to them. Numerous methods of targeted drug delivery have been described; not all include the
use of targeted moieties, as some are based on physical principles or physiological features of
the targeted area.[15, 20]
1.1.2.1 Passive targeting
The so-called Enhanced Permeability and Retention (EPR) eﬀect is considered the basis
of passive targeting and is commonly mentioned, in relation with tumours, infarcts, and
inﬂammation areas. Tumours grow quickly and require constant access to nutrients and oxygen;
therefore they stimulate the production of blood vessels. Growths of blood vessels are known
as angiogenesis. The fast growth leaves the endothelial cells of the blood vessels poorly aligned
with large fenestrations between them. This large spaces (200 - 800 nm) allows the drug carriers
to leak from the blood vessels into the tumour, as illustrated on ﬁgure 1.2. This way, the
drug carriers can bring the pharmaceutical agent into the tumour with the increased vascular
permeability, and release the API. The size of the fenestrations diﬀers from case to case, making
it possible to control the eﬃciency of the EPR eﬀect, from the size of the drug carrier.[15, 21]
Figure 1.2: A schematics of passive targeting and the EPR eﬀect. The drug carriers (micelles)
extravagate through the leaky vasculature and accumulated in the tumour, by cause of the poor
lymphatic drainage. Taken from Jhaveri and Torchilin [21].
In addition, the too fast blood vessels growth, the lymph vessels are also aﬀected.
Compressing them in the central portion of the tumour induces total collapse of the vessels,
which results in poor lymphatic drainage. Both concepts allow the leakages of drug carriers and
blood plasma components into the tumour, simultaneously letting them accumulate and reach
a high concentration.[21]
Long-circulation time is a key component of passive targeting in order to obtain a suﬃcient
level of accumulation in the tumour. To preserve the drug carriers in the blood circulation, the
carriers are "masked" with water-soluble polymers, by grafting them on to the carriers surface.
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This was proven by Torchilin and Trubetskoy [22] in their investigation of protective eﬀect of
polymers on nano-particulate drug carriers, where they look at the ﬂexibility of polymers.[21, 22]
1.1.2.2 Active targeting
Passive targeting is an eﬀective and valuable method, but there are some pathological situations
where the vascular endothelial cells remain unaﬀected by the frequent growth, making no
opportunity for the EPR eﬀect to progress. The diseased area is often not that diﬀerent from
healthy tissue when it comes to vascular permeability, temperature and ph. A more universal
and natural way of increasing drug targeting is trough active targeting. Active targeting explores
the fact that certain proteins are overexpressed on the surface of the cancer cells and can be
used to speciﬁcally recognise them. A wide range of moieties have been applied for the purpose,
including antibodies and their fragments, peptides, proteins, sugars and small molecules (see
ﬁgure 1.3).[9, 14, 15, 21, 23]
Figure 1.3: An illustration of drug loaded micelles, with diﬀerent targeting functions.
Antibody-targeted micelle (A), ligand-targeted micelles (B) and micelle with a cell-penetration
function (C). Taken from Jhaveri and Torchilin [21].
Antibodies are the most popular and frequently applied moieties, due to the high speciﬁcity
of their interactions, together with the diversity of their targets. However, although antibodies
are popular, there are some challenges related to their use. When determining the eﬀectiveness
in targeted drug delivery, important parameters include blood circulation through the target,
the targets size, numbers of binding sites for the target drug carrier in the target, and the
number and aﬃnity of targeting moieties on the drug carrier. One of the challenges of using
antibodies is their size of ∼150 kDa, which inﬂuence the number of targeting moieties on
the drug carrier, which is an important parameter to consider when determining the systems
eﬀectiveness. Other challenges include stability considerations and engineering problems during
mass production.[15, 21]
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1.2 Polymeric drug delivery systems
Polymeric drug delivery can potentially be a solution to many problems with conventional drug
delivery, including degradation and loss of the therapeutic agent, harmful side eﬀects and poor
bioavailability.[24] The polymeric materials are in many aspects similar to the body's natural
components and are chemically synthesised, making them unaﬀected to xenobiotic materials.
Furthermore, they can be customized to achieve the desired physical and chemical properties
and are therefore often used as components or supporting materials of devices to transport the
therapeutic agent into the body.[25]
Polymeric DDS consist of soluble polymers, microcapsules, liposomes, micelles etc. Each of
the carriers has its own advantages and dis-advantages, so the decision on which carrier to use
in a speciﬁc project, requires certain consideration.[24] One of the notable factors is the carriers
ability to stay in circulation. There are several reasons for the importance of long-circulation:
1. It may be necessary for the carrier to stay in the blood for long periods, in order to maintain
a desired level of the therapeutic agent in the blood and to achieve a better availability.
2. Carriers can over time accumulate in pathological sites with aﬀected vasculature such as
tumours, and thereby improve or enhance the delivery to these areas. The so-called EPR
eﬀect.
3. Prolonged circulation can help achieve more eﬃcient targeting eﬀect for the target modiﬁed
carriers.
From a clinical standpoint, it is of great importance that the various carriers are relatively
small in size (100 - 200 nm), since it has been demonstrated that they eﬀectively accumulate
in tumours by the EPR eﬀect.[24, 26] The important pathways for elimination of the long-
circulation carriers are renal clearance, uptake by cells from the blood and extravasation, which
are all independent processes. However, extravasation is of speciﬁc relevance, since it is an
important factor for the bioavailability of the long-circulation carriers. This relevance and the
importance of size have leaded to dividing the carriers into extravasation and non-extravasation
ones, where the size threshold is the main diﬀerence. The non-extravasation group, where the
size is above 5 - 10 nm, consists of cells, particles, larger liposomes etc. The extravasation
group (below 5 - 10 nm) includes small liposomes, proteins, micelles etc., together with various
polymers that are more than 40 kDa.[24]
1.2.1 Micelles
Micelles belong to a large family of dispersed systems, which are deﬁned as systems with two or
more phases with a well-deﬁned interface. In this family, micelles belong to colloidal dispersions,
which can be further divided into three principal groups: lyophilic, lyophobic and association
colloids. Micelles are classiﬁed as association or amphiphilic colloid.[24]
Amphiphilic colloids are formed spontaneously by amphiphilic molecules, at certain
conditions. Amphiphilic molecules consist of two distinct regions with opposite aﬃnities towards
a given solvent. At low concentration the molecules do not interact with each other in the solvent.
However, increasing the concentration can result in aggregation. These aggregates contain a
number of molecules in a spherical shape, and are known as micelles. The speciﬁc concentration
values at which the micelles are formed are known as the critical micelle concentration (CMC).
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At the CMC point, both the interface and bulk of the solvent become saturated with molecules
and further increase in concentration lead to the formation of the micelle within the bulk phase.
The relative CMC for amphiphilic molecules diﬀer from each another. Micelles produced from
small amphiphilic molecules have a high CMC and are unstable at high dilution values, where
large amphiphilic molecule micelles have a rather low CMC, making them very stable upon
strong dilution.[24]
Figure 1.4: General schematic, of formation of micelle from amphiphilic molecules. Taken
from Jhaveri and Torchilin [21].
Micelles are structured in a way that their outer surface, which is exposed to their aqueous
surroundings, consists of compounds that do not react with blood or tissue components. This
particularity feature allows micelles to remain in the blood for a long time, without being
recognized by the immune system. This is an important feature for a drug carrier.[24, 27]
The Kraﬀt point is another important parameter, which describes the micellization process
and follows to some extend the principles of CMC. The amphiphilic polymers exist as unimers
below the Kraﬀt point and as micelles and unimers above.[24, 28]
1.2.1.1 Micellization
The formation of micelles can be understood through thermodynamics. Micelles are
spontaneously formed because of the balance between entropy and enthalpy, where the driving
force becomes the decrease of Gibbs free energy (G). The free energy decreases when the entropy
increases as a result of core formation, which allows for packing of the hydrophobic blocks away
from the aqueous environments; this is also called the hydrophobic eﬀect. When the system
is at or just above the CMC, the micelles are loose, and still contain a small percentage of
water in their core. The micelle packing becomes tighter, more stable and size reducing, as the
concentration of the surfactant rises above the CMC. With the increase in concentration, the
remaining water is pushed out and the system equilibrium is shifted further towards micelle
formation.[21, 24, 28]
At a low CMC value, the size and stability eﬃciency for a monomer surfactant is high. The
decrease in CMC therefore results in an increase of the size and stability eﬃciency. This fact
is of great importance from a pharmacological point of view. When micelles are used as a drug
carrier in any biological system, they are diluted by biological ﬂuids, e.g. blood. Only micelles
with low CMC value will be stable at these conditions; at high CMC values the micelles will
dissociate into unimers.[24, 28]
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1.2.1.2 Solubilisation of micelles
Figure 1.5: A schematic plot of poorly soluble
compounds vs. the concentration of the surfactant.
Taken from Nell et al. [29].
Micelles ability to increase the solubility of
poor hydrophobic drugs is a signiﬁcant prop-
erty in the pharmaceutical industry. If the
solubility of poorly soluble compounds were to
be plot as a function of the concentration of
surfactant, it would show that the solubility is
very low until the concentration obtains CMC.
This is illustrated in in ﬁgure 1.5. Above
the CMC the solubility increases linearly to-
gether with the surfactant concentration, in-
dicating that the solubility is connected to
micellization.[24, 29]
Micelles formed of non-ionic surfactants are
commonly known to have an anisotropic water
distribution within their structure, where the
water content decreases from the surface
towards its core. The anisotropic water
distribution leads to a polarity gradient, indicating that the spatial position of the solubilized
drugs in a micelle is dependent on its own polarity. Consequently, nonpolar molecules will
solubilize in the core of the micelle. Polar molecules will be absorbed on the surface, and
the intermediate polarity substances will be distributed along surfactant molecules in speciﬁc
intermediate positions. The micelles drug loading capacity depends on various factors like the
chemical structure of the drug and the applied surfactant molecules, polarity of the drug, the
location of the drug, pH and temperature etc. The length of the hydrophobic region of a
surfactant molecule, in an aqueous environment, has an eﬀect on the drug loading capacity of
the micelle. An increase in the length helps the solubilisation of a hydrophobic drug inside the
micelle core and simultaneously increasing the core size.[24]
Thermodynamically speaking, solubilisation is considered as a normal barrier of the drug
between two phases (micelle and aqueous). The standard free energy of solubilisation (M G◦s)
can be expressed by the partition coeﬃcient (P ):[24, 29]
M G◦s = −RTln(P ) (1.1)
Where R are the universal gas constant and T the absolute temperature. From equation 1.1
it can be determined that the free energy decreases as a result of the drug entering the micelle
phase, as long as the drug is hydrophobic.[29]
The loading capacity of polymeric micelles, expressed by P , can be inﬂuenced by diﬀerent
factors, such as the compatibility between the hydrophobic region and the drug, the molecular
characteristics and solution temperature. However the most important factor regarding the
solubilisation capacity of polymeric micelles is the compatibility between the drug and the
hydrophobic region, based on many individual studies. Therefore is the choice of the hydrophobic
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region crucial that determines loading capacity and stability of the micelles. The compatibility
can be assessed by a Flory-Huggins interaction parameter (χsp), which is deﬁned as:[30]
χsp = (δs − δp)2 · Vs
kT
(1.2)
δs and δp are Scatchard-Hildebrand solubility parameters, where the index "s" and "p"
respectively represents the solubilised drug and polymer (hydrophobic region). Vs is the
molecular volume of the solubilized, k is the Boltzmann constant and T is the temperature
in Kelvin. The lower the χsp parameter, the greater the compatibility degree.[24, 30]
In 2004 Liu et al. [31] demonstrated that by considering the physical and chemical properties
of a drug of interest (Ellipticine), a suitable polymer could be found trough comparison and
calculations of the partial solubility parameters "s" and "p". These are then used to ﬁnd the
compatibility degree between the drug and polymer and improve formulation development in
the future.[31] The compatibility degree also has an inﬂuence on the release rate of the drug
from micelles. In the situation where the drug becomes more compatible with the hydrophobic
region, a decrease in release rate can be expected.[24, 30]
Loading of a therapeutic agent into micelles implements stability, long circulation, better
bioavailability and accurate loading conditions. However the drugs physical and chemical
properties, like the hydrophobic/hydrophilic balance in the drug, can contribute to either a
slow or fast release. The drug can be too stable in the micelle core, because of its partition
coeﬃcient (P ) is too high.[24]
1.2.2 Polymeric micelles
Polymeric micelles represent a separate class of micelles and are formed by polymers containing
both hydrophilic and hydrophobic parts, so-called copolymers.[32, 33] Copolymers contain two
or more diﬀerent monomeric groups organized in a polymeric chain, contrary to homo-polymers
that are built of identical monomeric units.[24, 34] Copolymers can be divided according to their
diﬀerent arrangements, as seen in table 1.2.
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Table 1.2: The main structural arrangements of copolymers. The A and B stand for diﬀerent
monomers. Inspired by Whitehurst [35].
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A and B refer to two diﬀerent monomeric units, where A can refer to a hydrophilic unit and B
a hydrophobic unit. Since copolymers are built from diﬀerent monomeric units, their properties
can be diﬀerent along the length of the chain. The block copolymer is a linear polymer with long
uninterrupted sequences of the monomeric units in its chain and can therefore have a various
ranges of blocks in its molecule. Since there is a distribution of A and B sequence, as well as their
length can they be written as: AxBy (di-block), AxByAx (tri-block), AxByAxBy (tetra-block),
which can be shortened to: (AxBy)n (multi-block). x, y and n represent average values.[27, 34]
It have repeatedly been proven that amphiphilic block AB-type copolymers with a hydrophilic
block sequence, exceeding to some extent that of the hydrophobic block, form spherical micelles
in aqueous solution. If the hydrophilic sequence becomes too large compared to the hydrophobic,
micelles will not be formed and the copolymers will exist as unimers in water.[24] Micelles
typically have a core-shell structure (see ﬁgure 1.4), that have a size distribution of 10-200 nm in
diameter, depending on fabrication.[33, 36] Their small size makes them capable of extravasation
through the leaky vasculature of tumour tissues and long-circulation, as mentioned in section
1.2. An advantage of polymeric micelles is their high structural stability, when compared to
surfactant micelles, which can be contribute to the entanglement of hydrophobic polymer chains
in the inner core. Additionally are the micelles core stabilized by the corona of hydrophilic
polymeric chains.[24] The stability has two aspects, static and dynamic; the static is deﬁned by
the CMC, which is very low compared to surfactant micelles and the dynamic aspect is deﬁned
by the low dissociation rate of micelles.[24, 32, 33]
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1.3 Mechanisms of endocytosis
Studying the inﬂuence of nanoparticles on the interactions during endocytosis is especially
important for developing eﬀective and safe nanoparticle drug delivery systems. Some knowledge
has been derived from studies, with radiolabelled or ﬂuorescent nano-materials like quantum
dots, copolymers, liposomes etc. The studies focus primarily on the transport and eﬀect of
nano-materials throughout the body, by looking at their endocytic pathways or their impact on
a narrow amount of cellular organelles. Very little has been done on combining the physical and
chemical properties of the engineered nanoparticles with the cellular response. The same can be
said for research into the properties of nano-materials that determine subcellular targeting.[37]
Figure 1.6: Representation of the diﬀerent mechanisms of endocytosis. There are a wide
spread of pathways for particle or solvent uptake. In all cases, the initial stage proceeds from the
membrane, involving engulfment of particle or other material into cellular vesicles. Afterwards
the uptake is sorted through endosomes, where the uptake is transported to its ﬁnal destination,
to be recycled or transported across the cell. CCV: Clathrin-coated vesicles. CLIC: Clathrin-
independent carriers. GEEC: Glycophosphatidylinositol-anchored protein. Taken from Sahaya
et al. [38].
The endocytosis process for nano-carriers, represent the active transport of nano-carriers,
such as large molecules, particles and micelles into living cells. There are diﬀerent types of
endocytosis mechanisms; the main types are phagocytosis and pinocytosis.[39, 40] Phagocytosis
is mainly associated with phagocytes (protecting cells), but other cells like ﬁbroblast cells may
also possess the phagocytic ability. The phagocytosis mechanisms can be divided in three steps:
1) Opsonisation of the nano-carriers in the bloodstream, where they are marked so that they can
be targeted by phagocytes. 2) Recognition of the now opsonized nano-carrier by the phagocytic
cells (receptors). 3) Internalization, where the nano-carriers are engulfed and the formation of a
phagosome; a vesicle forms around the nano-carrier, where its size is dependent on the size of the
carriers. The opsonisation step of the phagocytosis is the cause of the nano-carrier systems short
time in the blood circulation, because they are easily opsonized. However nano-carrier systems
with a hydrophilic surface are less opsonized, making the carriers less inclined for recognition,
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which leads to longer circulation time.[41] The pinocytosis process includes the formations of
caveolae and clathrin, as well as caveolae/clathrin-independent uptake, which depend on speciﬁc
compounds and mechanics. The pinocytosis is referred to as cellular drinking, because it ingests
soluble material from the surrounding environment by enclosing it in small uniform vesicles.
Unlike phagocytosis, pinocytosis is a constitutive process that occurs continuously, whereas
phagocytosis has to be triggered.[40, 41]
When exposing a biological system like cells, proteins or DNA to nano-materials, a series of
nanomaterial/biological (nano-bio) interfaces materialize. The interfaces depend on dynamic
bio-physiochemical interactions, kinetics and thermodynamic transactions between the two
surfaces. It is not possible to describe all the interactions at the nano-bio interface with certainty,
but the assembled knowledge provides a theoretical framework to describe some.[37]
1.3.1 Interface boundaries and forces
At the formation of the nano-bio interface, there exists a plethora of dynamic components. Three
of these are: 1) the nanoparticle surface, which includes shape, size and curvature characteristics,
determined by the physical and chemical composition of the nanoparticle; 2) The solid-liquid
interface, starting when the nanoparticles interacts with the surrounding medium; and 3) The
solid-liquid interface contact zone with biological substrates. The contact of the nanoparticles
with charged or hydrophobic regions of the cell regulates the preferred pathway for interaction
with the cellular environment, and the route of internalization and metabolism.[37, 42]
Figure 1.7: Schematics of the interface between
a nanoparticle and a lipid bilayer. The following
element of the nano-bio interface are shown: 1)
the nanoparticle surface (black sphere) 2) the solid-
liquid interface, with the surrounding medium (red
sphere) and nanoparticle interaction 3) The solid-
liquid interface contact zone, which are shown as the
nano-bio interface. Taken from Nell et al. [37].
Each component has an inﬂuence on the in-
terface between the nano-materials and the bi-
ological system. Some of the most important
properties of the nanoparticle surface, that
have an inﬂuence on the interface, include the
chemical architecture of the materials, func-
tionalization, porosity, crystallinity and hy-
drophobicity. Other properties like zeta po-
tential, aggregation and biodegradability are
determined by the suspending medium, to-
gether with the pH, temperature and exis-
tence of other organic molecules. These char-
acteristic properties contribute in determin-
ing the forces that occurs at the nanoparti-
cle/medium interface (solid-liquid interface),
which demonstrate some of the principles seen
between colloidal particles; van der Waals
forces (VDW), electrostatic interaction (re-
pulsive) or short range interactions from the
charge and solvent interaction.[37] For exam-
ple, if the particle material was SiO2, then it is
known from colloid science that typical inter-
actions between SiO2 particles include attrac-
tive VDW forces and repulsive electrostatic
forces, the sum of which yields the Derjaguin-
Landau-Verwey-Overbeek (DLVO) theory, if the particles are dissolved in water. When it comes
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to biological ﬂuids, the ionic strength often becomes higher around 150 mM, which indicates
that the electrostatic forces are more likely to be observed only a few nano-meters from the
surface. Furthermore, the high ionic strength covers the zero-frequency contribution from the
VDW forces. The solvating force is also of importance, especially for inorganic and hydrophilic
nanoparticles, by increasing stability through "hydration pressure" or "hydrophilic repulsion".
Alternatively the surrounding ﬂuid will dry out (dehydration) and aggregation will arise, caused
by interaction at the surfaces hydrophobic attraction or hydrophobic eﬀect.[37]
In understanding the nano-bio interface, the most challenging task is to characterise the
solid-liquid interface at the contact zone. From a theoretical point of view, this interface is often
assumed to have steady-state behaviour, due to the bulk properties of suspensions, such as net
charge and average aggregation size. However, when considering the nano-bio interface, this
approach must be adjusted. For instance, looking at a nanoparticle interacting with a ﬁbroblast
cell, the forces are similar to the interaction between two nanoparticles. An important diﬀerence
however is the cell membrane. Fibroblast has a ﬂexible membrane, which can change its shape
elasticity under the inﬂuence of temperature or shear stress. Furthermore, a dynamic biological
system contributes with an inhomogeneous environment, as a result of distribution and speciﬁc
structural localization of proteins and lipids on the membrane surface. This result in a non-
uniform distribution of charges, indicating that the nanoparticles may be exposed to diﬀerent
forces.[37] The continuous changes come from environmental inﬂuences, together with cellular
housekeeping, e.g. a medium's properties can be changed by secreted cell products. There
are many diﬀerent interactions that may inﬂuence the biological system, which can change
the characterising of the solid-liquid interface at the contact zone, and thereby the nano-bio
interface. The size of a nanoparticle also has an inﬂuence on the interaction, as cells have a
heterogeneous surface on the length scale of 10 - 50 nm in diameter, due to the presence of
the surface proteins together with other structures. Thus, a micro-particle would experience
a balanced energy level covering the surface, whereas a nanoparticle (10 - 50 nm) might not
experience any change or interactions, depending on its speciﬁc location. With the possibility
for endocytosis, the complications for the interactions accumulate and become very diﬃcult to
predict theoretically.[37] It will take time to investigate all the diﬀerent interaction and explore
theses interfaces in the same amount of detail as in colloidal chemistry.[37]
1.3.2 Protein corona
When nanoparticles are suspended in a biological ﬂuid, they are instantly coated with proteins.
The absorbed proteins can undergo conformational changes that can lead to exposure of
altered functions and/or avidity eﬀects. The protein corona is an important factor in the
following surface properties of nanoparticles: charge, hydrodynamic size of the particle and
the resistance to aggregation. The concurrent exchange of free proteins in the medium, together
with the kinetics of protein association and disassociation, are important when determining the
nanoparticle interactions with the cell surfaces and their receptors. [37]
The nano-material surface composition determines which biomolecules interact with the
surface and thereby inﬂuence the particle interactions with the cell. Diﬀerent proteins are
known to form complexes with nanoparticles, the nature of which is aﬀected by the dissociation-
dissociation rates, respective binding interactions between speciﬁc particle types and the
biological medium. Furthermore, the concentration of proteins surrounding the particle have
an inﬂuence on the binding of the proteins, and the creation of the corona. Albumin,
immunoglobulin and ﬁbrinogen are proteins that bind strongly to polymeric micelles, carbon
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nanotubes and liposomes. Immunoglobulin is a common antigen in the human body, which
protects and leads to opsonisation of pathogens or particles, hence promoting phagocytosis
[43].[37, 44]
1.3.3 Particle wrapping of a surface membrane
The nano-bio interface principles can be observed with particle adhesion to a cellular surface,
which results in the wrapping of the cells membrane. The wrapping of the membrane at the
adhesion sites depends upon speciﬁc and non-speciﬁc interactions to overcome the elastic forces
of the membrane, opposing particle uptake. The "wrapping time" or the time for cellular
uptake can be determined mathematically from diﬀerent factors such as size, shape, energy of
the system and elasticity of the cell membrane. Some factors have been mentioned in section 1.2,
like that the optimal size for a spherical particle is between 10-50 nm. Surface ligand provide an
eﬀective means for binding interaction, thereby allowing the particle to interact with molecules
or receptors on the cell membrane. Furthermore, a protein corona also eﬀects the wrapping
eﬃciency depending on its nature, thermodynamics and receptor diﬀusion.[37]
Figure 1.8: For particle uptake to be established, some speciﬁc or non-speciﬁc binding
interaction have to occur. Shown above is the speciﬁc binding interaction (Ligands - receptor),
that is driven by a decrease in free energy at the adhesion sites to overcome the elastic forces.
The particles coated with speciﬁc ligands that react with the respective receptors. The red circles
represent nanoparticle, with ligands attached to their surface, shown as the yellow dots. The
ligands interact with the Y-shaped receptors. The blue ellipses denote the protein clathrin,
which is engaged in the energy-dependent uptake of particles. Taken from Nell et al. [37].
These interactions conclude in a pinocytosis process called receptor-mediated or clathrin-
mediated endocytosis, a process that is associated with drug delivery. In order to accomplish
this process, the receptors must be present at the adhesion site by diﬀusion, for the formation
of a number of critical interactions. Receptor diﬀusion establishes a resistive force with
an optimal rate constant to attain wrapping. The number of receptors that diﬀuse to the
membrane therefore inﬂuence the wrapping process, since a limited number of receptors could
restrain particle wrapping. It is not necessary that the ligands are of biological origin; they
can be constructed of chemical functional groups, metallic sites, polymer or surface function
modiﬁcation that promotes binding aﬃnity. One criteria is that they potentially result in
endocytosis or direct penetration of the membrane. Direct penetration is observed for Au
nanoparticles with amphipathic compounds arranged on their surface, allowing them to slip




Curcumin is derived from the rhizome of the spice Curcuma longa. Curcumin has a wide
spread of biological and pharmacological abilities; it is anti-inﬂammatory, an anti-oxidant,
can be used to combat tumours among others.[46] Curcumin is a yellow/orange crystalline
powder, with the chemical structure C21H20O6 and is a bis-α,β-unsaturated β-diketone, which
is commonly named diferuloylmethane. [47, 48] This indicates that curcumin exhibits keto-
enol tautomerism with a predominated keto form in neutral and acid solutions and a stable
enol in a basic medium. Commercially available curcumin is a mixture of three natural
curcumin analogues from the Curcuma longa spice; diferuloylmethane, demethoxycurcumin,
and bisdemethoxycurcumin, which represents, respectively approximately 77%, 17% and 6% of
the mixture. [48, 49]
Figure 1.9: The chemical structure represents curcumin and its natural analogues from its
origin spice Curcuma longa, in addition to its important metabolites. The red circles indicate
the curcumin analogues applied in the commercially available curcumin mixture. Taken from
Anand et. al [49].
Curcumin is soluble in acetone, ethanol and dimethyl sulfoxide (DMSO) and insoluble in
water and ether. It has a melting point of 183 ◦C and a molecular weight of 368.37 g/mol.
Curcumins colour appearances are dependent on the pH value of the aqueous environment; at
the pH level of 2.5 - 7, curcumin will appear yellow while for pH > 7 it will appear red. In aqueous
solutions the stability of curcumin is enhanced for high pH values, but it is only soluble at a
low pH value. [50, 51] This is contrary to organic solutions, where curcumin is both stable and
soluble at acidic ph. At unstable conditions deﬁned as aqueous medium at neutral pH or higher,
it degrades to ferulic acid and feruloylmethane. In a phosphate buﬀer system with a pH of 7.2,
>90% of curcumin will rapidly degrade over a period of 30 min; antioxidants can prohibit this
degradation, indicating that the degradation is caused by an oxidative mechanism. Degradation
is extraordinary slow at pH values between 1 - 6, which are the conditions experienced in
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the stomachs environment. In cell culture mediums with 10% foetal bovine serum (FBS) and
human blood, curcumin is more stable; after 1 h <20% curcumin will start to degrade and at
8 h approximately 50% will have degraded. Fluorescence of curcumin can be observed as a
broad band at diﬀerent wavelengths, depending on the suspending solvent; in acetonitrile at
λmax= 524 nm, in ethanol at λmax= 549 nm and in micellar solutions at λmax= 557 nm. Some
structures can be seen in toluene at λmax= 460 - 488 nm.[50, 51]
In the last couple of decades, great eﬀort have gone into isolating curcuminoids, a collective
expression for curcumin analogues from other sources, including Curcuma longa, Curcuma
zedoaria and Curcuma aromatica. Curcuma zedoaria and Curcuma aromatica are in close
relation to Curcuma longa , and several groups have investigated and compared their biological
and pharmacological activities.[49]
1.4.1 History
Throughout human history, plants have been used for various purposes and have evolved
alongside all life. These plant-based products are millions of years old. Thousands of these
products have originated as secondary metabolites, to protect the plants from their environment,
diseases and infections. One of the many applications of the plants is as medicine, where they
have had an important impact on health care in many ancient and modern cultures. In India a
system of holistic medicine known as Ayurveda1 use many plant-based drugs to treat diﬀerent
diseases, including cancer. The modern medicine have not encouraged or held nature based
medicine in high account With a better understanding of the molecular mechanisms of some
nature-based medicine products, the therapeutic abilities of plants can be fully understood. [50]
Curcuma longa also called Turmeric, is an Indian spice belonging to the ginger family, which
contains the active component curcumin, has been thoroughly investigated for its therapeutic
use. The curcuminoids represents 3-5% of this spice [50]. Turmeric has a long history as a
medicinal plant and has remained holy from time immemorial. In India this spice has many
names; golden spice, spice of life and the earthy herb of the sun and in ancients times it was
considered a holy spice the one herb above all others. Turmeric can be documented for its
medical use for at least 6000 years in India.[47]
Turmeric is primarily cultivated in India, but is native to the south-east Asia, where related
Curcuma plants grow in the wild, which it itself is not known to do. Other countries, like China,
Indonesia and Thailand also cultivated Turmeric, but Indian Turmeric is considered the best
on the world market, making India the world's largest producer, consumer and exporter. In
a year (2002-2003) there was produced around 636000 tons of turmeric plants from an area of
175190 ha; this is 20.6% of the production of spices in India from 5.5% of the growth area. The
production of Turmeric have increased annually by 7.6% in the past 30 years.[47]
1.4.2 Medical properties of curcumin
Curcumin is mostly known as a dietary spice or colouring agent in food and textile, but is
additionally used as treatment for a wide variety of ailments. Investigations concluded over the
past four decades have provided indications of how many and which ailments curcumin have
an inﬂuence on. It has been found to reduce blood cholesterol, repress symptoms of type II
1An alternative medicine used in Hinduism, where the person is considered on a physical, psychological, social,
and spiritual plane to prevent disease.
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diabetes, and speed up wound healing among other things. Some of the medical properties of
curcumin can be seen in ﬁgure 1.10.[40]
Figure 1.10: A representation of the medical properties of curcumin. Reproduced from
Alberts et. al [40].
From all these studies, it is shown that curcumin aﬀects a large number of targets, including
growth factors, receptors, enzymes and gene regulating apoptosis. This multi-targeting ability
might explain its therapeutic potential against cancer. Extensive studies have shown that due to
the complexity and multiple signalling pathways including cancer evolution and growth, drugs
that have an ability to target several diﬀerent mechanisms, are more eﬀective towards cancer,
compared to the monotargeted anticancer drug currently in use.[52]
Curcumin has been shown to be eﬀective against diﬀerent variations of cancers, including
leukaemia along with breast-, lung- and brain cancer. Regarding various malignant glioblastoma
cells - a class of brain tumour cells resistant towards chemotherapy and radiation - it has
been observed that curcumin inhibits the NF-κB signalling pathways in all the cell lines.
Furthermore, curcumin aﬀects a variety of other mechanisms, including the induction of non-
apoptotic autophagy cell death, the inhibition of G6PT gene expression and the activation of
both receptor-mediated and mitochondria-mediated proteolytic pathways etc.[52] In the study
by Aoki et al. [53], the authors have shown that curcumin induces apoptosis of malignant glioma
cells through naturally regulated destructive mechanisms both in vitro and in vivo. In the study,
U87-MG cells were inoculated in an adult nude mouse and grown to a tumour of a volume of 50 -
70 mm3. Afterwards intratumoral injections of curcumin every 24 h for 7 days were administered.
The curcumins eﬀect was evaluated on day 16 of the initial treatment. The experiment resulted
in a threefold decrease in the tumour volume, compared to the control.[52, 53]
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1.4.3 Curcumin loaded micelles
Although curcumin has great therapeutic potential and numerous applications to combat disease,
its further development in clinical applications is hindered by its poor solubility, poor oral
bioavailability and its fast degradation in the body.[54, 55] In order to fully exploit the potential
of curcumin, an injectable drug formulation with controlled release properties, as well as
protection from hydrolytic degradation, is needed for clinical applications.[46, 54, 55] In the study
performed by Yang et al. [46], they produced curcumin encapsulated polymeric micelles by a
single-step solid dispersion method, and investigated the curcumin micelles cytotoxicity in vitro,
along with their size, stability, cellular uptake and their anti-tumour activity. The curcumin
micelles had a size of 27.6 nm in diameter, and were found to be relatively stable for 48 hours
after preparation. The cytotoxicity investigation has shown that curcumin micelles and free
curcumin eﬃciently suppresses the growth of colon carcinoma cells, while blank micelles showed
only a minor cytotoxicity as a drug carrier. The cellular uptake has been investigated using
ﬂuorescence microscopy and ﬂow cytometry, where the cells incubated with curcumin micelles
exhibited a larger amount of apoptotic bodies, when compared to cells with free curcumin.
The study concludes that curcumin loaded micelles inhibited the growth of colon cancer, by
enhancing the cellular uptake of curcumin and increasing apoptosis induction.[46]
In an another study performed by Liu et al. [55], they produced curcumin loaded
polymeric micelles with a small particle size and high drug loading, through a one-step solid
dispersion method, and investigated their characteristics as a potential water-based formulation
of curcumin, along with the cytotoxicity the in vitro release behaviour and their anti-tumour
activity. The curcumin micelles had a size of 28.2 nm and had archived a relatively high
encapsulation eﬃciency of 98.91 %; additionally these curcumin micelles were stable and soluble
in aqueous solutions. The release behaviour of curcumin micelles and free curcumin was
investigated through a dialysis method, which revealed a fast release of free curcumin. Curcumin
micelles however had a much slower and suitable release rate, indicating its applications as a
drug delivery system by minimizing the curcumin exposure to healthy cells. The cytotoxicity
investigation has shown that free curcumin and curcumin micelles eﬃciently inhibit growth
of 4T1 cells, while blank micelles indicated a very low cytotoxicity. The curcumin micelles
showed a higher cytotoxicity activity than free curcumin, suggesting that the micelles enhance
the cytotoxicity of curcumin. The anti-tumour eﬀects of free curcumin, curcumin micelles and
blank micelles showed that blank micelles exhibited no anti-tumour eﬀect, when compared to
free curcumin and curcumin micelles, that both suppress the growth of tumours. The study
concluded that curcumin micelles are an attractive water-based formulation of curcumin, with




Cell viability is often mentioned in the context of cryopreservation, but is not commonly deﬁned
in articles, so its exact meaning is often obscure. This is undesirable, since it can lead to
a wrong interpretation of results.[56] Often cell viability is deﬁned as the amount of healthy
cells or damaged cells in a sample. Measuring cell viability is important for cell culturing as
well as to cytotoxicity assays. Typically toxicity assays are run continuously over a period of
time to investigate cell proliferation for a given initial population. There are a many diﬀerent
cell viability methods, which can be loosely characterised by the assays used to analyse the
population and the individual cells. The assays that analyse the population are the most rapid,
but provide less detailed information compared to the individual analysis.[57]
Over time viability assays have become more complex and more optimization oriented.
Trypan blue dye exclusion assays are widely used assays today, but it was also one of the earliest
methods and was based on a basic principle: Healthy viable cells have an intact membrane,
while dead cells have a damaged membrane, indicating that the intact membrane can exclude
the trypan blue dye, where the damaged membrane has lost control of its pathways into the cell,
leaving it to appear blue. The methods is characterised as an individual cell assay, so the cells
can be counted by the use of a microscope or an automated counting device. These counts can
then be used to ﬁnd the percent of viable cells in the sample. However, this method does have
some disadvantages; it has been indicated that the number of dead cells increase upon adding
the dye, thereby requiring the cells to be counted quickly [58]. [57]
With time new dyes, which rely on the metabolic activity of the cells, have become more
popular, since they can used on adherent cells and thereby lead to high-throughput analysis.
New technology has also resulted in providing major advantages, in the form of measurements.
By using a plate reader, multiple treatment groups can be screened in a short time period. For
optimization of viability assays, multiple method exist for investigations into the mechanisms
of cell death; examples include the Resazurin-based methods and live/dead staining and the
inﬂuence of dyes on the cells. In conclusion, the optimal viability assay varies depending on the
cell type and culture conditions, and as such than one method should be used to conﬁrm the
individual assays.[57]
The cytotoxicity assay used in this thesis is a method of estimating the number of non-viable
cells present in a multiwell-plate. The assay measures the release of lactate dehydrogenase
(LDH) from cells with a damaged membrane. The LDH released from the cells to the growth
medium are measured by a 10 min coupled enzymatic assay, thereby measuring the enzymatic
activity of NADH dehydrogenase. NADH's activity results in the conversion of resazurin into
resoruﬁn. Resofurin is a ﬂuorescent, which is being generated in proportion to the amount of
LDH. This reagent mix does not harm healthy cells, making it possible to measure LDH release




Glioblastoma are also called grade IV astrocytoma, and are a part of a group of tumours
which arise from glial cells or supporting tissue in the brain, called glioma. Astrocytoma is
one type of glioma, named after the star-shaped cells (astrocytes) from which they grow. [60]
Figure 1.11: A diagram of astrocyte cells. Taken
from Cancer Research Uk. [61].
The degree of astrocytoma abnormality
is described with grades, on a scale of
I to IV. Glioma tumours with a grade
of I are considered benign, whereas grade
II are also considered benign, but require
frequent monitoring by MRI or CT scan
every 6 - 12 months. Malignant glioma and
high-grade glioma are terms for grades III
and IV, where grade III has an increased
growth index compared with grade I and II.
Tumours are also grouped by their growth
rate: slow growth (low grade), moderate (mid-
grade) and rapid (high-grade), where grade
III astrocytomas are considered to have mid-
grade growth rate. [60]
Figure 1.12: An light micrograph of the cell line
U87 glioma in DMEM + 10% of FBS. Taken from
de Almeida Sassi et al. [62].
Glioblastoma is the highest grade of glioma
and is the most common and fatal primary
brain tumour in humans. The National
Institutes of Health (NIH) has found it to have
the highest incidence rate among inter cranial
malignity in the last 40 years. Glioblastoma
develops rapidly from its onset and exhibits no
clearly recognizable morphological changes in
the cells before it reaches grade III. In elderly
patients (over 55 years), it is characterized
by a rapid growth rate and short survival
time. Younger patients (under 45 years) in
some cases exhibit epilepsy due to low-grade
gliomas, which in time progress to a secondary
glioblastoma. The occurrence of secondary
glioblastoma are seen in ∼5% of the patients,
and can only be diagnosed trough historical
evidence of the tumours evolution or clinical
observations. [60, 63, 64]
For newly diagnosed patients, the standard treatment would be a surgical procedure for total
removal of the tumour and, if possible, chemotherapy and radiation therapy to remove any
remnants. The overall survival is 15 months, though 2 - 5% of patients may survive 3 years or
more. The variation in survival rate is closely related to the patients performance status, which
is deﬁned from the individual patients. A young age is advantageous. Treatment options are
limited and the survival rate has not changed much over the years, when compared to other
cancer types. A cure has not been found for glioblastoma, but trough research and clinical
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trials, the understanding of the disease progression has been found: molecular alterations in
signalling pathways and small improvements in patient responses to treatment, is a step in the
right detection. [60, 63, 64]
1.5.2 Fibroblast
Figure 1.13: The connective-tissue cell family.
The arrows indicate the interconversions within the
family. Fibroblast is shown as single cell. Taken from
Alberts et al. [65]
Fibroblast is a part of a bigger group of cells,
the family of connective-tissue cells. The
connective-tissue cells are any variation of
cells found in the connective-tissue, such as
ﬁbroblast cells, fat cells, bone cells, cartilage
cells and smooth muscle cells. The connective-
tissue is the structural framework of the body,
where it accompanies and supports all other
tissue. The connective-tissue itself is formed
by ﬁbroblasts spread out by the collagenous
extracellular matrix (ECM), which is a com-
plex network of polysaccharides and ﬁbrous
proteins secreted by cells. These networks are
only secreted by the ﬁbroblast, bone and car-
tilage cells. Fibroblast cells are a central part of the ECM structure; it produces the structural
proteins, adhesive proteins and amorphous gel-like substances that make up the cell. Addition-
ally they play other roles beyond structural their purposes. It is responsible for the ECM's main-
tenance and reabsorption, inﬂammation, angiogenesis, cancer progression and wound healing.
When an injury occurs on the skin or in tissue, the ﬁbroblast cells closest by start multiplying
and migrating into the wound and create countless of collagenous matrices. These will isolate
and reconstruct the damaged skin or tissue.[65, 66]
Figure 1.14: An light micrograph of conﬂuent
primary human ﬁbroblast cells grown in CnT-05
medium. Taken from CellnTec [67]
The family of connective-tissue cells is a
fundamental part of the support and repara-
tion of tissues and organs, and their ability
to redeﬁne or rebuild themselves depending
on the circumstances is of great importance.
This allows the cells to undergo change and
respond to many types of damage. This abil-
ity to advance in the face of changes and their
conﬁned lifestyle, is a good explanation as to
why the cells are easy to grow in a culture.
[65]
The ﬁbroblasts display the ability to trans-
form into other family members, but despite
this there are there some uncertainties about
this interconversion. Evidence indicates that
ﬁbroblast cells are essentially diﬀerent in var-
ious areas in the body, and may be diﬀerent
for each region in the body. The maturity of
the ﬁbroblast cell has an inﬂuence on their transformation ability. A mature ﬁbroblast cell is
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less capable of transforming, and exists alongside immature ﬁbroblast cells, which can develop
into an assortment of mature cells. [65]
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2.1 Material
Table 2.1: An overview of all chemicals, equipment and software used in this project. All
solutions were prepared with mili-Q water produced at the laboratory using a Silhorko water
treatment plant.
Name Manufacturer Description
0.22µm Sterile Filter Jet Bioﬁl PES membrane, 250 mL
4 well chambered slides Thermo Fischer Scientiﬁc Borosilicate
Cellstar Multiwell culture
plate
Sigma Aldrich 96 well, F-bottom, with lid
Culture ﬂask Thermo Fisher Scientﬁc T25, T75, T125
Round-bottom polystyrene
tubes
Thermo Fisher Scientiﬁc 5 mL
(3-Aminopropyl)
trimethoxysilane (APTMS)
Sigma Aldrich > 97%
Acetone Sigma Aldrich > 99.5%
Chloroform Sigma Aldrich ≥99.9%
Curcumin Sigma Aldrich Powder, stored at -20◦C,
from Curcuma longa
(Turmeric)
CytoTox-ONE Promega CytoTox-ONE Assay kit
DMEM (1x) Gibco, Thermo Fisher Scien-
tiﬁc
Glutamax
Dynasore hydrate Sigma Aldrich Blocks dynamin-dependent
endocytosis, stored at -20◦C,
protected from light
Ethanol (EtOH) Kemetyl 96%
Ethylenediaminetetraacetic
acid (EDTA)
Bie & Berntsen 0.02% in PBS, stored at -
20◦C
Fibroblast (CRL 2429),
Homo sapiens, from skin
tissue
Courtesy of the stem cell
group at Aalborg University
Foetal Bovine Serum(FBS) Invitrogen/VWR Stored at -20◦C
Formaldehyde Sigma Aldrich Formalin solution
Glioblasstoma (U87), Homo
Spaiens, from brain tissue
Courtesy of the stem cell
group at Aalborg University
Hoechst 33342 Invitrogen A nucleic acid stain, emits
blue ﬂuorescence
Horse Serum Invitrogen/Fisher Scientiﬁc Stored at -20◦C
Pernicillin/Streptomycin
(P/S)
Invitrogen/VWR Stored at -20◦C
Continues on next page
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Table 2.2: An overview of all chemicals and equipment used in this project. All solutions




Thermo Fisher Scientiﬁc pH 7.4, without calcium and
magnesium
Polyvinylpyrrolidone(PVP) Countesy of Prof. M. Shtil-
man " Biomaterials" center,
Mendeleyev University. [68]
Sodium azide Merck Millipore Very toxic, stored at room
temperature
Toluene Sigma Aldrich ≥99.5%, ACS reagent
Tryple Thermo Fisher Scientiﬁc Replacement for trypsin, gen-
tle towards cells, stored at
room temperature
Trypsin (T) Invitrogen/VWR Stored at -20◦C
Wortmannin Sigma Aldrich Penicillium funiculosum,
≥98%, (PI3-K) inhibitor
Equipment Manufacturer Description
NanoSight LM10 Malvern Sample chamber, microscope
and camera
NanoSight NTA 2.1 Malvern Software
Steri-Cycle CO2 incubator Thermo Temperature at 37
◦C and 5%
CO2
PixeLink Digital camera PixeLink For light micrograph
PixeLink Capture OEM PixeLink Program
Olympus CKX41 Olympus Microscope
Axio Observer.Z1 Carl Zeiss Inverted ﬂuorescent micro-
scope
AxioCam MRm Carl Zeiss Digital Camera
Zen 2012 Carl Zeiss Software
Vibra Cell Sonics Sonication Probe
Ultrasound Bath VWR Branson Ultrasonics 2510
Centrifuge Eppendorf 5804R
CHRIST Alpha 1-4 LD plus
freeze dryer
Sciquip Ltd.
Multimode Atomic Force Mi-
croscope (AFM)
Bruker Tapping mode
WSxM WSxM solutions Software for AFM images
Multimode Plate reader Perkin Elmer EnSpire
CytoFlEX S Flow cytometer Beckman Coulter 4 Laser(30mW, 638nm 50mW
and 405nm 80mW) 13 Fluo-
rescent Detectors





The chemical structure of the PVP polymer used throughout this project, can be observed in
ﬁgure 2.1. The polymer is available with diﬀerent unit mass at 1 and 6 kDa.
Figure 2.1: The chemical structure of the polymer used throughout this project: PVP-COOH,
where R=C18H37.
2.2.1 Synthesis of loaded micelles
In this project micelles with diﬀerent loaded hydrophobic materials, such as curcumin and
chloroform, was explored. The micelles formed with chloroform are considered empty micelles.
The approach for synthesis of the diﬀerent micelles diﬀers, depending on the solvents applied.
2.2.1.1 Micelles loaded with curcumin
50 mg of PVP polymer was dissolved in 8 mL milli-Q water, while 5 mg curcumin (Sigma
Aldrich) was dissolved in 1 mL acetone (Sigma Aldrich) simultaneously. The two solutions were
then mixed in a Greiner centrifugation tube and sonicated using a sonication probe (Sonics) for
10 minutes (pulse, 1 s on, 2 s oﬀ, Amplitude 40%) The Greiner tube was stored in ice to prevent
overheating. After the sonication, the solution was frozen in liquid nitrogen and lyophilised
in the vacuum freeze dryer (Sciquip Ltd.). The dehydrated powder is then stored at room
temperature, wrapped in aluminium foil to protect it from light.
2.2.1.2 Empty micelles
50 mg of PVP polymer was dissolved in 8 mL milli-Q water. 1 mL chloroform (Sigma Aldrich)
was added to the polymer solution and then sonicated in a sonication probe (Sonics) for 10
minutes. (Pulse 1 s on, 2 s oﬀ, Amplitude 40%) The Greiner tube was placed in ice to prevent
overheating. The sonicated solution was frozen in liquid nitrogen and lyophilised in the vacuum
freeze dryer (Sciquip Ltd.). The dehydrated powder is then stored at room temperature.
2.2.2 Nanoparticle tracking analysis
Size distribution was determined using Nanoparticle Tracking Analysis, through their properties
of light scattering and Brownian motions in a liquid suspension. Suspended micelles were injected
into the sample chamber, where a laser beam was passed through, scattering the light, and
making the micelles easily visible in the microscope. The NanoSight microscope (Malvern)
was equipped with a video camera, that records a video ﬁle of the Brownian motions of the
micelles. The Nanoparticle Tracking Analysis (NTA) software (Malvern) used the video to track
individual micelles, and used diﬀerent equations to determine their diameter.[69]
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2.2.2.1 Preparation of untreated sample
The intended amount of lyophilised micelles was weighed and dissolved in the equivalent amount
of mili-Q water in order to reach a concentration of 1 mg/mL. The suspended micelles was
sonicated in an ultrasound bath (VWR) for 60 min and centrifuged (Eppendorf) for 10 min at
10000 rpm, 21◦C. A 1 mL luer syringe was used to transfer the prepared micelle solution to the
NanoSight (Malvern) sample chamber. Through the microscope a position, where a signiﬁcant
amount of moving micelles (ca. 10 or more) can be observed, was found by adjusting focus
and moving the sample. Then a 160 sec video ﬁle of the micelles was record with the NTA
software (Malvern). Parameters were adjusted (detection threshold, blur and screen grain), so
each observed micelle was marked with one cross and the processing was started. The obtained
data are then processed in MatLab (MathWorks).
2.2.2.2 Preparation of ultrasonically dispersed samples
The lyophilised micelles was weighed and dissolved in the milli-Q water, to create a 1 mg/mL
solution. A 1 mL luer syringe is used to transfer the prepared micelle solution to the NanoSight
(Malvern) sample chamber. Through the microscope a position, where a signiﬁcant amount (ca.
10 or more) of moving micelles can be observed, was found, by adjusting focus and moving the
sample. Then a 160 sec video ﬁle of the micelles were record with the NTA software (Malvern).
Parameters were adjusted (detection threshold, blur and screen gain), so each observed micelle
was marked with one cross and the processing was started. The obtained data are then processed
in MatLab (MathWorks).
2.2.3 AFM imaging
The AFM imaging was performed using a Bruker Multimode AFM Nanoscope IIIa in tapping
mode. The tapping mode is especially well adapted to soft samples, because of its complete
reduction of the lateral force on the sample [70]. An Olympus 24OTS silicon-based cantilever,
with a resonance frequency of 68 kHz and a force constant of 1.43 - 2.47 N/m, was used for
imaging of the polymeric micelles. Alternatively, a Scan Sens HA-NC silicon-based cantilever
with a resonance frequency 140 kHz and a force constant of 3.5 N/m was used. An either freshly
cleaved or chemically modiﬁed mica surface were used as a substrate for depositing micelles.[71]
2.2.3.1 Sample preparation for AFM observations
Two preparation methods were applied for the AFM observation; drop deposition directly on
the mica surface (negatively charged surface) and drop deposition on an APTMS modiﬁed mica
surface (positively charged surface).
Freshly cleaved mica surface A solution of 1 mg/mL lyophilised micelles in milli-Q water
was prepared. The suspended micelles was sonicated in an ultrasound bath (VWR) for 60 min
and centrifuged (Eppendorf) for 10 min at 10000 rpm, 21◦C. 10 µL of prepared micelle solution
was deposited on the freshly cleaved mica surface by pipetting. The sample are left for 10
minutes, and then dried by blowing on the sample with N2.
APTMSmodiﬁed mica surface The freshly cleaved mica surface was incubated in a vacuum
chamber with a mixture of 250 µL APTMS (Sigma Aldrich) and 500 µL toluene (Sigma Aldrich)
for 30 min. Simultaneously the micelle solution is prepared. Prior to the modiﬁcation, the
chamber was ﬂushed and ﬁlled with argon to eliminate water vapour. The 1 mg/mL lyophilised
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micelles in milli-Q water solution was then prepared and sonicated in an ultrasound bath (VWR)
for 60 min , followed by centrifuging (Eppendorf) for 10 min at 10000 rpm, 21◦C. 20 - 30 µL of
prepared micelles solution was then deposited on the APTMSmodiﬁed surface through pipetting.
The sample was left for 5 - 10 minutes and then dried with N2.
2.2.4 Cell culturing
In this project two cell lines have been used for experiment: Glioblastoma (U87) and Fibroblast
(CRL 2429). All the experiments were performed in a sterile environment (Fume hood), there
have been cleaned with 70% EtOH (Kemetryl). The following protocols are identical for both
cell lines.
2.2.4.1 Preparation of DMEM 10% FBS 1% P/S growth medium
1 mL of P/S solution (VWR) and 10 mL of FBS solution (VWR) were added to 500 mL DMEM
growth medium (Gibco). The medium was then ﬁltered through a 0.22 µm sterile ﬁlter (Jet
Bioﬁl) by vacuum pump, in to a sterile container. The DMEM 10% FBS 1% P/S growth medium
are stored at 4◦C.
2.2.4.2 Preparation of 2 % Horse Serum DMEM 1% P/S growth medium
1 mL P/S solution (VWR) and 2 mL Horse Serum (Invitrogen) were added to 100 mL DMEM
growth medium (Gibco). The solution was then ﬁltered through a 0.22 µm sterile ﬁlter (Jet
Bioﬁl) by vacuum pump into a sterile container. The 2% Horse Serum DMEM 1% P/S growth
medium are stored at 4◦C.
2.2.4.3 Preparation of T/E solution
T/E solution was prepared by ﬁrst diluting trypsin (VWR) 1:10 in PBS, and then ﬁlter it
through a 0.22 µm ﬁlter (Jet Bioﬁl) by vacuum pump. Then EDTA (Bie & Berntsen) was
dissolved to 0.002% solution and ﬁltered through a 0.22 µm ﬁlter as well. The two solutions
were mixed 1:1, resulting in a 0.125% /0.01% T/E solution.
2.2.4.4 Preparation of PBS solution
PBS 10x solution (Thermo Fisher) was diluted 1:10, with mili-Q water and ﬁltered through a
0.22 µm ﬁlter by vacuum pump, into a sterile container. The PBS solution are stored at room
temperature.
2.2.4.5 Starting cell culture
A cell culture was started by preparing 14 mL DMEM 10% FBS 1% P/S growth medium. The
medium was transferred to a T75 cell culture ﬂask and incubated at 37◦C for approximately 20
minutes. A 1 mL vial containing approximately 1 million cells suspended in DMSO was thawed,
and immediately after transferred to the headed growth medium. The cells and medium were
mixed by pipetting. The cells are incubated overnight at 37◦C and the growth medium was then
changed. Subsequently the growth medium was change every two or three days, until the cells
have reached 80 - 100% conﬂuent.
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2.2.4.6 Passing or splitting cells
For splitting and passing the cells when they have reached 80 - 100% conﬂuent, the growth
are removed from the T75 cell culture ﬂask. The cells were washed with ﬁltered PBS and
trypsinated by adding 1.5 mL of T/E to cover the bottom of the culture ﬂask. The amount of
T/E solution required depends on the size of the culture ﬂask. The cells are incubated at 37◦C
for 5 - 10 min, until the cells are lifted from the surface. 5 mL of growth medium was added
to the culture ﬂask to stop the trypsination, which is toxic to the cells if they are exposed to it
for too long. The desired amount (1/5 or 1/10) of cell solution was transferred to a centrifuge
tube and centrifuged (Eppendorf) for 5 minutes at 1000 rpm, 21◦C. The growth medium was
removed from the centrifuged tube and 5 mL of fresh growth medium was added. The cells
and the medium were mixed by pipetting. The re-suspended cells were transferred to a new
T75 cell culture ﬂask, which has been prepared with 10 mL heated medium; if needed, they
can alternatively be prepared for counting. For counting the cells, 10 µL of the re-suspended
cells were transported to a counting chamber where they can be counted, and cell solutions with
speciﬁc cell concentration can be obtained. The T75 cell culture ﬂask was incubated at 37 ◦C.
The growth medium has to be changed every two or three days, until the cells have reached 80
- 100% conﬂuent.
2.2.4.7 Transfer of cells to multiwell-plates
For transferring cells to multiwell-plates (Sigma Aldrich), the cells was ﬁrst prepared by passing,
as described in section 2.2.4.6. Instead of transferring the cell solution to a culture ﬂask, they
were counted to obtain a desired cell concentration. 50% of the multiwell-plate well volume was
ﬁled with growth medium. The cell solution obtained from the passing was diluted to a suitable
volume and cell concentration, for the required amount and size of wells. 50% well volume of the
diluted cell solution was added to each well. The multiwell-plate were incubated at 37 ◦C and
grow until the cells was suitable for experimentation. The growth medium has to be changed
every two or three days.
2.2.5 Cytotoxicity assay
The CytoTox-ONETM Homogeneous Membrane Integrity Assay kit (Promega) was used to
estimate the % of damaged cells in a multiwell-plate. The speciﬁc method used can be seen in
section 1.5.
Reagent preparation
1. Thaw and equilibrate Substrate Mix and Assay Buﬀer to room temperature (22 ◦C).
2. The CytoTox-ONE Reagent was prepared by adding 11 mL Assay Buﬀer to a vial of
Substrate Mix.
3. Gently mixed to dissolve the substrate mix.
Protocol
- Set up a multiwell-plate (Sigma Aldrich) containing cells in growth medium (Cell seeding
concentration depends on plate size).
- Incubate the multiwell-plate until the cells have reached 80% conﬂuence.
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- Each well was photographed for documentation of conﬂuence and amount of cells.
- Discard the growth medium.
- Wash once with PBS (Thermo Fisher).
- Add the micelle solutions, which have been dissolved in 2% Horse Serum supplemented
medium (see method 2.2.4.2), to the appropriate wells.
- After 24 hours of incubation at 37◦C were the multiwell-plate removed and equilibrated
to 22◦C (approximately 20 - 30 minutes).
- Each well was photographed again.
- To generate a positive control, the maximum LDH release has to be detected; for
this a lysis solution was used. Add 2 µL of lysis solution per 100 µL original volume,
to the positive wells. Incubate for 5 min at 37◦C. Before the multiwell-plate was
equilibrated to 22◦C.
- Transfer 100 µL of medium to a grey multiwell-plate.
- Add 100 µL of CytoTox-ONE Reagent to each well and mix or shake for 30 sec.
- Incubate at 22 ◦C for 10 minutes, making sure that the sample is not exposed to light.
- Add 50 µL of Stop solution to each well, in the same order of addition that was used for
adding the CytoTox-ONE Reagent.
- Shake plate for 10 seconds.
- The ﬂuorescence was record with an excitation wavelength of 560 nm and an emission
wavelength of 590 nm in the multi-plate reader (Perkin Elmer).
2.2.6 Fluorescence microscopy of drug uptake in vitro
The following preparations were carried out in 4 well borosilicate chambered slides (Thermo
Fischer), with a total volume of 1 mL. The chamber slide was later examined in the ﬂuorescence
microscope (Carl Zeiss), where they were exposed to diﬀerent ﬁlter channels. The channels
depend on the dye or ﬂuorophore used to stain the cells: DAPI have an excitation wavelength
at 353 nm and emission wavelength at 465 nm, which were channelled through a 335 - 383 nm
excitation ﬁlter and a 420 - 470 nm emission ﬁlter. FITC have an excitation wavelength at
495 nm and emission wavelength at 519 nm, which were channelled through a 450 - 490 nm
excitation ﬁlter and a 500 - 550 nm emission ﬁlter. DsRed have an excitation wavelength at
545 nm and emission wavelength at 572 nm, which were channelled through a 538 - 562 nm
excitation ﬁlter and a 570 - 640 nm emission ﬁlter. The DAPI was used to channel out Hoechst
dye, which is a blue ﬂuorescent that stains the nucleus of eukaryotic cells. The FITC and DsRed
channels out ﬂuorescence of curcumin.
Solution preparation
- Dynasore hydrate (Sigma Aldrich): 50 µL per. 4 mL growth medium.
- Worthmaninn (Sigma Aldrich): 0.43 µL per. 4 mL growth medium.
- Hoechst Dye (Invitrogen): Dilute 1:1000 in PBS (Thermo Fischer).
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Exposing cells to endocytosis inhibitors, by incubation The growth medium was
removed from the cells and 50% well volume of dynasore hydrate or worthmaninn were added
to the respective marked wells. The 4 well chambered slides were incubated for 30 min at 37◦C.
Exposing cells to micelles and free curcumin A micelle solution was prepared
by dissolving lyophilised micelles in the equivalent amount of growth medium, to reach a
concentration of 1 mg/mL. The micelle solution was centrifuged (Eppendorf) for 5 min at 1000
rpm, 21◦C. 50% well volume of the prepared micelle solution were added to the 4 well chambered
slides, and was incubated for 30 min at 37 ◦C. Subsequently, the wells were washed carefully
with PBS (Thermo Fischer), until the colour from curcumin was no longer seen. 100% well
volume were ﬁlled with 4% formalin solution (Sigma Aldrich) and was then incubated at 37◦C
for 5 - 15 min. Preceding preservation, all the wells were washed twice with PBS and stored in
PBS at 4◦C. The wells are then ready for further experimentation.
Cells exposed to Hoechst dye To expose the cells to Hoechst dye, the wells were emptied
of growth medium or PBS (Thermo Fischer) and 100% well volume of Hoechst solution was
added to the wells. Subsequently the wells were incubated for 15 - 20 minutes at 37◦C. All the
wells were then washed twice with the solvent the cells originally were stored in; PBS or growth
medium. The wells were stored in the solvent used for washing at 4◦C.
2.2.7 Flow cytometric analysis
To investigate the cells endocytosis mechanism for uptake of the synthesised 6 kDa curcumin
micelles (CM), ﬂow cytometry was applied. Flow cytometry measures and analyses the various
physical characteristics of the cells, as they stream through a beam of light in suspended form.
Some of the characteristics measured are internal complexity, relative ﬂuorescence intensity and
the cells relative size. In this case, ﬂuorescent intensity will be directly linked to the amount of
curcumin that has been taken up by the cells. All the properties are determined by applying
an optical-to-electronic coupling system, which registers how the cells scatter, when deviating
incident laser light, and emit ﬂuorescence at range of wavelengths. The setup consists of three
main systems: ﬂuidics, optics and electronics.[72]
1. The ﬂuidics system transport the suspended cells to the laser, through a stream for
examination.
2. The optics system includes lasers, which illuminate the cells in the sample stream and the
optical ﬁlters, which directs the light signals to the relevant detectors.
3. The electronics system detects the light signals from the optics systems and convert it into
electronic signals that can be handled by a computer.
When the light is passing through the stream, it is refracted and deﬂected by the cells, which
produces scattered light. Any ﬂuorescent molecules present will ﬂuoresce and the emitted light
will be collected together with the scattered light by positioned lenses. A combination of ﬁlters
and beam splitters steers the collected light to the deﬁned detectors, which produces electronic
signals proportional to the optical signals. In this case, the scattered light will be collected by
the forward scatter (FSC) and the side scatter (SSC) photodiodes. The combination of FSC
and SSC signals can be used to evaluate the cells relative size and the internal complexity.[72]
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In order to elucidate the mechanisms of endocytosis, diﬀerent inhibitors capable of blocking
endocytic pathways of the cells, were used in combination with 6 kDa CM. To inhibit some
endocytosis mechanisms, dynasore hydrate and sodium azide were used. Dynasore hydrate
inhibits dynamin GTPase activity, together with dynamin dependent endocytosis.[73] Almost all
endocytosis mechanisms are dependent on energy processes; these mechanisms can be inhibited
by lowering the temperature and sodium azide at the same time.[74]
A CytoFlEX S Flow cytometer from Beckman Coulter was used for the study. It is equipped
with 4 lasers and 13 ﬂuorescent detectors. To determine the presence of curcumin in the cells
the channel PerCP was used, with laser excitation at 488 nm and ﬂuorescent emission 650 - 690
nm. The number of event measured for all the samples was 20000, whit a ﬂow rate of 30 µL/min
for the CRL 2429 samples and 60 µL/min for the U87 samples. The collected data were further
examined in the software CytoExpert (Beckman Coulter).
Solution preparation
- A Stock solution of 10% sodium Azide (Merck Milipore) was prepared by dissolving the
sodium azide in PBS (Thermo Fischer). From the stock solution, a 0,01% solution of
sodium azide dissolved in growth medium was produced.
- Dynasore hydrate (Sigma Aldrich): 50 µL per. 4 mL growth medium.
Protocol
- Cells were seeded, with a cell concentration of 40000 cells/mL in T25 culture ﬂasks with
a capacity of 6 mL. The seeding process for the culture ﬂasks are similar to transferring
to a multiwell-plate (see section 2.2.4.7).
- Incubate the T25 culture ﬂasks at 37◦C until the cells have reached 100% conﬂuence.
- The culture ﬂasks were emptied of growth medium and washed twice with PBS (Thermo
Fischer).
- Add 3 mL of inhibitor solution dynasore or 0.01% sodium azide to the culture ﬂasks.
Culture ﬂasks without inhibitors was incubated with 3 mL growth medium and control
culture ﬂasks (containing only cells) was incubated with 6 mL of growth medium.
- Incubate for 30 min at 37◦C or 4◦C, depending on the inhibitor.
- For this experiment sodium azide was incubated at both 4 and 37 ◦C.
- Add 3 mL of 6 kDa CM to culture ﬂasks with and without inhibitors and incubated for
another 30 min, at their respective temperature.
- The culture ﬂasks were emptied and washed once with PBS (Thermo Fischer).
- The cells were trypsinated by adding 3 mL of Tryple (Thermo Fischer), until the cells were
lifted from the surface.
- The cells solution was then transferred to centrifuge tubes and centrifuged (Eppendorf)
for 5 min at 1000 rpm.
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- Empty the centrifuge tubes for tryple and re-suspended the cells in 3 mL PBS (Thermo
Fischer) and transfer the cell solution to 5 mL round-bottom polystyrene tubes (Thermo
Fischer).
- The cellular uptake was then measured and analysed with a CytoFLEX S Flow cytometer
(Beckman Coulter) with a 448 nm laser.
34
3. Results and Discussion
3.1 Production of micelles
Various micelles were synthesised using two PVP polymers of diﬀerent sizes (1 and 6 kDa),
as well as curcumin and chloroform. Curcumin is used as a hydrophobic model drug, to give
an indication of the cellular uptake of the micelles. In itself it is considered eﬀective towards
cancer and many other diseases, and its ability to act as a ﬂuorescent dye, makes it a favourable
model drug. Furthermore curcumin helps to stabilise the micelles, by creating a hydrophobic
core together with the octadecane in the polymer. Chloroform helps to temporally stabilise
the micelles, in order to synthesis possible empty micelles. Both curcumin and chloroform are
strong hydrophobes, and are small with molecular weights of 368.37 g/mole and 119.38 g/mole
respectively; that property gives them the possibility of forming small stable micelles. They will
create tension in the hydrophobic region of the polymer molecules when incorporated into the
core.
The procedure used to synthesise the curcumin and chloroform loaded micelles, as described
in section 2.2.1, is an oil-in-water method; this means that an aqueous solution of the polymer is
prepared, and a solution of curcumin in an organic solvent is added to from an oil-in-water
emulsion. The encapsulation of curcumin happens when the organic solvent evaporates in
the freeze dryer. Chloroform is an organic solvent, and will evaporate in the freeze dryer,
theoretically leaving the micelles empty. The lyophilised micelle powder synthesised in this
project is shown in the pictures in ﬁgure 3.1. These are only some of the many batches
synthesised and applied in this project.
(a) (b) (c)
Figure 3.1: Photographs of the diﬀerent synthesised lyophilised micelle powders in greiner
tubes. (a) is 1 kDa lyophilised micelle powder. (b) is 6 kDa lyophilised micelle powder and (c)
is 6 kDa lyophilised empty micelle powder.
The appearance of the lyophilised powders diﬀers when comparing the two PVP polymer sizes.
The 1 kDa lyophilised powder appears to have a more ﬂaky texture in its powder structure and
a bright yellow colour, whereas the texture of the 6 kDa lyophilised powder is smoother and
uniformly structured and has a slightly darker yellow colouring. These diﬀerences in colour and
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texture can be a result of the size diﬀerence, or a result of the freezing with liquid nitrogen,
where parts of the solution may have adhered to the tube sites, resulting in a ﬂaky texture.
3.1.1 Size distribution
The polymer size, together with the solvents curcumin and chloroform has been shown to have
an inﬂuence of the size distribution of the various micelles. In the following graphs showing the
size distributions of the various synthesised micelles have been provided. The lyophilised powder
has been prepared by dissolving a given amount of it in an equivalent amount of milli-Q water,
to reach a concentration of 1 mg/mL. Afterwards some solutions are treated with ultrasound
treatment and analysed with the NanoSight. The two preparation methods can be seen in
sections 2.2.2.1 and 2.2.2.2. The data was collected from the NTA software and processed with
Matlab. During the processing, the data were limited to 0 - 400 nm, instead of 2000 nm. The
data above 400 nm showed nothing speciﬁc, and was as such deemed unimportant.
3.1.1.1 Curcumin loaded micelles
The graphs observed in ﬁgure 3.2 illustrate the size distribution of a 1 kDa CM sample with and
without ultrasonic treatment. The graph in panel (a) is the 1 kDa CM sample which has been
treated with ultrasound treatment, as described in section 2.2.2.1. The size distribution range
from 34 - 370 nm. This graph show a broad spectrum of sizes, with four peaks at 82, 112, 154
and 200 nm. The highest concentration of micelles is seen at 82 nm.
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Figure 3.2: 1 kDa CM synthesised using the procedure in section 2.2.1.1 to produce micelles
loaded with curcumin. Panel (a) shows the size distribution graph obtained from the NanoSight
analysis for the 1 kDa CM sample with ultrasound treatment (section 2.2.2.1). Panel (b) shows
the size distribution graph obtained from the NanoSight analysis for the 1 kDa CM sample
without ultrasound treatment (section 2.2.2.2).
The graph in panel (b) illustrates the size distribution graph for the 1 kDa CM sample,
without ultrasound treatment. The graph shows a high concentration of micelles at 80 nm and
some lower peaks at 38, 202 and 271 nm respectively, with a size distribution ranging from 28 -
342 nm.
On ﬁgure 3.3 two size distribution graphs for 6 kDa CM are illustrated, with and without
ultrasound treatment. The graph in panel (a) shows the 6 kDa CM solution treated with
ultrasound treatment. The size distribution ranges from 25 - 400 nm, with one clear peak
observed at 142 nm.
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6 kDa Curcumin micelles
(b)
Figure 3.3: 6 kDa CM synthesised using the procedure micelles loaded with curcumin section
2.2.1.1. Panel (a) shows the size distribution graph obtained from the NanoSight analysis for
the 6 kDa CM sample with ultrasound treatment (section 2.2.2.1). Panel (b) shows the size
distribution graph obtained from the NanoSight analysis for the 6 kDa CM sample without
ultrasound treatment (section 2.2.2.2).
The graph in panel (b) on ﬁgure 3.3 shows the 6 kDa CM solution without ultrasound
treatment. Here is a broad size distribution ranging from 20 - 400 nm shown, with some
indications of individual peaks at 116, 180 and 227 nm. The highest concentration of micelles
is seen at 227 nm.
Since the micelles are stored as a lyophilised powder after being synthesised, they still
contain some remnants of free polymer chains and an excess of curcumin. Theses residues
can be form through by-products like micro-aggregates, which is seen in the NanoSight as broad
size distribution spectra, together with badly dissolved micelles. The ultrasound treatment
is therefore necessary to properly dissolve the lyophilised powder; additionally the solution
is centrifuged, to force precipitation of the residues. Another possibility is to change the
synthesising method to include rotary evaporation in vacuum, in order to eliminate the solvent,
but re-suspending it after this can prove diﬃcult if the lyophilised powder cannot be easily
dissolved. It is inadvisable to centrifuge the micelle solution after sonication, since it contains
an organic solvent; it is not safe and could result in the removal some of the curcumin from the
micelle core.
When comparing the size distribution of 1 and 6 kDa CM, it becomes clear that the polymer
size has an inﬂuence on the result. The 1 kDa CM has a diameter of 80 nm, while 6 kDa CM have
a diameter of 142 nm. 1 kDa CM are smaller and have a narrow size distribution, and results in
a higher concentration of micelles in the analysed solution. The 6 kDa CM are almost twice as
big as the 1 kDa CM and their size distribution are broader. This indicates that the synthesis
with 6 kDa polymer produces fewer and larger micelles, together with more free polymer chains,
whereas 1 kDa polymer produces a large amount of small micelles, with free polymer chains.
However during the experiments it was observed that 1 kDa CM was more diﬃcult to dissolve
than 6 kDa CM, which can be a result of the ﬂaky powder texture of 1 kDa CM. Nonetheless
when comparing the graphs for 1 kDa CM in ﬁgure 3.2, it can be seen that the sample that was
treated with ultrasound and centrifuged, is the sample with the broadest size distribution and
gives the most imprecise indication of the micelles size. This is in contrast to the sample without
ultrasound treatment, which has a narrow size distribution and a clear particle size at 80 nm.
This may possibly indicate that the ﬂaky structures in the 1 kDa CM texture are PVP polymer
37
3. Results and Discussion
residues and a small excess of curcumin, there have not produced micelles, which where dissolve
by the ultrasound treatment. 1 and 6 kDa CM have been synthesis with the same proportions
of PVP polymer and curcumin, which may not have been ideal. From the size distribution, it
is seen that a 6 kDa CM solution contains large and few micelles, while a 1 kDa CM solution
contains small and numerous micelle along with polymer residue. This might imply that 1 kDa
polymer require a more curcumin, when synthesising 1 kDa CM. Thereby producing a 1 kDa
CM solution containing a higher amount of small micelles and less polymer residue.
In studies by Yang et al. [46] and Liu et al. [55], the synthesised micelles are much smaller,
as compared to the ones synthesised in this project. The molecule mass of the polymer in these
article are not presented, making it problematic to fully compare them to our results. In addition
a diﬀerent method of synthesizing the micelles is applied, which also can have an inﬂuence on
the diﬀerent observed results.
3.1.1.2 Empty micelles
On ﬁgure 3.4 two size distribution graphs for empty micelles are shown, with and without
ultrasound treatment. The graph in panel (a) illustrates the ultrasound treated empty micelle
solution. It is seen that the size distributions are very broad, ranging from around 10 nm to above
400 nm. The highest concentration of micelles is seen at 40 nm in diameter. Other individual
peaks are seen at 27, 61, 111, 139, 246 and 365 nm. The concentration of these micelles is not
as high as observed at 40 nm. On the graph in panel (b), the empty micelles solution treated
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Figure 3.4: Empty micelles synthesised using the procedure from section 2.2.1.2 to produce
micelles loaded with chloroform. Panel (a) shows the size distribution graph obtained from the
NanoSight analysis for the empty micelle sample with ultrasound treatment (section 2.2.2.1).
Panel (b) shows the size distribution graph obtained from the NanoSight analysis for the empty
micelles sample without ultrasound treatment (section 2.2.2.2).
without ultrasound treatment is seen. The graph shows a high concentration of micelles at 41
nm, as well as a broad size distribution from 10 - 400 nm. There are indications of other peaks
along the distribution around 31, 82, 110, 135, 199 and 263 nm, with lower concentration of
micelles than at 41 nm.
The very broad size distribution graphs seen in ﬁgure 3.4 for both empty micelles solutions
indicate, that there is a high concentration of PVP polymer residues in the solutions. The
empty micelle solution treated with ultrasound treatment is smother, and gives a small clear
peak at 40 nm, where a large concentration of undissolved micelles and residues have been
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removed from the solution. It still shows a broad size distribution, which can be a result of
aggregated micelles or polymer chains still residing in the solution. However, when comparing
the empty micelles size with those of 1 and 6 kDa CM, they are very small and very few in the
solution, which can be a result of the high concentration of polymer aggregates and residues.
The empty micelles have a size of 40 nm, which is twice the size of 1 kDa CM and almost
four times the size of 6 kDa CM. The empty micelles small size, high concentration of polymer
aggregates and residues, can be directly linked to the use of chloroform. Chloroform helps to
temperately stabilize the hydrophobic core, but evaporates when lyophilised, which resulted
in less stable empty micelles. Where the curcumin loaded micelles still remains stable after
lyophilised, because of the curcumin in their core. The stability of the empty micelles is not
very high, which can result in the concentration of monomers become lower when dissolving
the micelles for experimentation. The are no hydrophobic interactions to hold the monomers
in place in the micelles, making them loss and leaves a high concentration of monomers in the
micelle solution. This can be observed in the NanoSight results, panel (a) and (b) ﬁgure 3.4
both shows broad size distribution, there are, as mentioned, a resulted of polymer chains and
aggregates residing in the solutions.
All the small individual peaks seen in some of the size distribution graphs such as in ﬁgure 3.2
and panel (b) in ﬁgure 3.3 can be the results of large micelles or aggregates being over represented
in the NTA software. The large micelles or aggregates migrate slowly across the screen, because
of their large size, which makes them over represented in the NTA softwares statistics. Some
micelles might not have been marked in the NTA software resulting in incomplete statistics.
3.1.2 AFM imaging of micelles
The synthesised micelles were observed with a Bruker Multimode AFM Nanoscope IIIa operating
in tapping mode on mica. In the following ﬁgures the obtained images and height proﬁles from
cross-sections of the various synthesised micelles are shown. The lyophilised powder was weighed
and dissolved in an equivalent amount of milli-Q water, to reach a concentration of 1 mg/mL.
Afterwards the solutions were treated with ultrasound and drop deposited on either APTMS
modiﬁed mica or freshly cleaved mica. The two methods are described in section 2.2.3.1. The
images where processed in the WSxM software.
3.1.2.1 Empty micelles
Figure 3.5 shows two AFM images of synthesised empty micelles, that have been treated with
ultrasound before being drop deposited on an APTMS modiﬁed mica substrate or a freshly
cleaved mica substrate, as well as two height proﬁles. Panel (a) in ﬁgure 3.5 shows the APTMS
modiﬁed mica substrate and two small deposited micelles. The blue line across the micelles
represents their cross-sections. The cross-section proﬁles from panel (a) can be seen on panel
(b). The proﬁles show structures with heights ranging from 5 - 7 nm and 60 nm across.
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(a) (b)
(c) (d)
Figure 3.5: AFM images of empty micelles, produced by loading micelles with chloroform
as described in section 2.2.1.2, and their height analysis. Numbers decide the respective cross-
sections. Panel (a) and (c) represents AFM images of empty micelles treated with ultrasound
treatment and drop deposited on a APTMS modiﬁed mica substrate or a freshly cleaved mica
substrate, see section 2.2.3.1. Panel (b) and (d) represents the cross-section proﬁles of the blue
lines in panel (a) and (c).
Panel (c) shows the freshly cleaved mica substrate and the deposited micelles. The deposition
pattern is random across the mica substrate and some of the presumed micelles look to be
aggregates of multiple micelles, with a variety of sizes. The blue lines represent cross-sections of
some of the randomly deposited micelles. The graph in panel (d) shows the cross-section proﬁles,
which illustrates the structures height and width. The three cross-sections show a height ranges
from 1 - 2.5 nm and a width length of 25, 40 and 55 nm.
When comparing the two AFM images in ﬁgure 3.5 panel (a) and (c), there is an obvious
diﬀerence in concentration of deposited micelles between the two. On the APTMS modiﬁed
mica substrate only two empty micelles are seen, whereas on the freshly cleaved mica substrate
large amount of presumably empty micelles are observed. This gives an indication of the empty
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micelles surface charge, since the APTMS modiﬁed mica is positively charged and the freshly
cleaved mica is negatively charged, it results in positively charged empty micelles. The height
proﬁles also implies that the micelles seen in panel (a) of ﬁgure 3.5 are less collapsed than the
micelles observed in panel (c), where there is a height diﬀerence around 2 - 3 nm. The height
proﬁle in panel (b) appears more uneven across its structure, where two peaks can be seen,
which may result in a broader width. It can also be a result of a collapsed core, but the graph
does not show a signiﬁcant decrease in the curve, which would be expected for a collapsed core.
The height proﬁles in panel (d) shows a more well deﬁned and broad peak for its cross-sections,
resulting in a more reliable presentation of the micelle width. The micelles on the negatively
charged surface (panel (c)) are more collapsed on the surface, resulting in broad widths and a
small height proﬁles.
Comparing the empty micelles size obtained from the NanoSight to those obtained with the
cross-section proﬁles, a diﬀerence is seen. One of the cross-sections proﬁles in panel (d) in ﬁgure
3.5 shows a width of 40 nm, which corresponds to the size seen in panel (a) in ﬁgure 3.4. However,
when the micelles are deposited on the mica surfaces, they collapse on the oppositely charged
surface, due to the interaction forces, between the positively charged micelles and the negatively
charged mica surface. This results in broader micelles than observed in the size distribution
analysis.
3.1.2.2 Curcumin loaded micelles
Figure 3.6 shows two AFM images of synthesised 1 kDa CM, that have been treated with
ultrasound before being drop deposited on a APTMS modiﬁed mica substrate or a freshly
cleaved mica substrate, as well as two height proﬁles. Panel (a) in ﬁgure 3.6 shows the AFM
image of the freshly cleaved mica substrate and the deposited 1 kDa CM. The blue lines represent
cross-sections, which correspond to proﬁles seen in the graph in panel (b). A large variety of
randomly distributed micelles across the mica substrate are observed on panel (a), where some
looks collapsed and others appears to be deposited on top of each another. The proﬁles show
structures with heights ranging from 1 - 3.5 nm and very broad widths of 100, 225, 425 and 625
nm.
41
3. Results and Discussion
(a) (b)
(c) (d)
Figure 3.6: AFM images of 1 kDa CM produced by loading micelles with curcumin as
described in section 2.2.1.1 and their height analysis. Numbers decide the respective cross-
sections. Panels (a) and (c) represents AFM images of 1 kDa CM treated with ultrasound
treatment and drop deposited on a freshly cleaved mica substrate or a APTMS modiﬁed mica
substrate respectively (see section 2.2.3.1). Panels (b) and (d) represent the cross-section
proﬁles of the blue lines in panel (a) and (c).
Panel (c) shows the AFM image of 1 kDa CM deposited on APTMS modiﬁed mica substrate,
where the blue lines represent cross-sections. The cross-section proﬁles, seen in graph in panel
(d) shows the structures heights, which range from 2.5 - 8 nm and a width of 450, 650 and 750
nm.
Figure 3.7 represents two AFM images of synthesised 6 kDa CM, that have been treated
with ultrasound before being drop deposited on a APTMS modiﬁed mica substrate or a freshly
cleaved mica substrate, as well as two height proﬁles. Panel (a) shows the AFM image of 6 kDa
CM deposited on freshly cleaved mica substrate, with blue lines representing cross-sections. On
the AFM image only three micelles are observed, which have a random distribution pattern. In
contrast to the AFM image in panel (c), the scale for this image is smaller, which results in
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smaller micelles in comparisons. The cross-section proﬁles can be seen in the graph in panel
(b), showing the height and width of the structures. A height range from 1 - 6 nm is shown
together with a width of 15, 95 and 120 nm. Some substrate irregularities from 0.5 - 1 nm can
be observed as well.
(a) (b)
(c) (d)
Figure 3.7: AFM images of 6 kDa CM produced by loading micelles with curcumin as
described in section 2.2.1.1 and their height analysis. Numbers decide the respective cross-
sections. Panels (a) and (c) represent AFM images of 6 kDa CM treated with ultrasound
treatment and drop deposited on a freshly cleaved mica substrate or a APTMS modiﬁed mica
substrate respectively, see section 2.2.3.1. Panels (b) and (d) represent the cross-section proﬁles
of the blue lines in panel (a) and (c).
Panel (c) illustrates the APTMS modiﬁed mica surface, with deposited 6 kDa CM. More
structures are observed in this AFM images, compared to the previously ATPMS modiﬁed mica
samples, with empty micelles (see panel (a) in ﬁgure 3.5) and 1 kDa CM (see panel (c) in ﬁgure
3.6 ). The blue lines in panel (a) represents the cross-sections proﬁles in the graph in panel (d).
The cross-section proﬁles show the structures heights, which range from 5 - 8 nm and width
lengths of 225, 325 and 375 nm.
43
3. Results and Discussion
The diﬀerence observed between the 1 and 6 kDa CM deposited on APTMS modiﬁed mica
substrate and freshly cleaved mica substrate, is that the micelles vary in size, amount and
appearance. The AFM images of 1 and 6 kDa CM deposited on freshly cleaved mica substrate,
seen in panel (a) in ﬁgures 3.6 and 3.7 show a great diﬀerence in concentration and size of
micelles. Only three micelles are observed for 6 kDa CM, whereas a great variety of randomly
distributed structures are observed for 1 kDa CM. The cross-section proﬁles for the 1 kDa CM
(panel (b) in ﬁgure 3.6), imply that the observed structures are collapsed, with an uneven surface.
The structures observed might not be curcumin loaded micelles, but PVP polymer chains there
have produced tightly packed micelles, with a small hydrophobic core. These tightly packed
micelles are a possible consequence of not suﬃcient curcumin in the synthesis process, leaving
the polymer chains to reach stability by tight packing. The cross-section performed on the
tightly packed micelles is very broad and have an uneven surface. Thereby indicating that the
micelles are was collapsed on the surface, with maximum height of 3 nm. When comparing these
cross-section proﬁles with those observed for 6 kDa CM (seen in panel (b) in ﬁgure 3.7), more
well deﬁned and broad peaks are seen, which give a more reliable representation of micelles.
The AFM image in panel (a) ﬁgure 3.6 for 1 kDa CM show few indications of little bright
dots, with surrounding coronas, which are presumed to be 1 kDa micelles loaded with curcumin.
The cross-section proﬁle for C in panel (a) ﬁgure 3.6 are a representative of one, which give a
more deﬁned and narrow peak compared to the observations of the tightly packed micelles. From
the NanoSight experiment it was observed that a 1 kDa CM solution treated with ultrasound
resulted in a broad size distribution, which implies polymer residues and micro-aggregates. This
corresponds well with the observations for the AFM image in panel (a). The AFM image might
have look diﬀerent, if the 1 kDa CM solution had not reserved ultrasound treatment, that
may have resulted in less tightly packed micelles and several curcumin loaded micelles instead.
Furthermore, the observations for 1 and 6 kDa CM deposited on freshly cleaved mica substrate
contradicts the observations done for empty micelles, which imply that the micelle surfaces were
positively charged and would be more attracted to the negatively charged surface. The few
micelles observed for 6 kDa CM and the observations done for 1 kDa CM indicates that the
curcumin micelles might not be positively charged.
When comparing the AFM images of 1 and 6 kDa CM deposited on a APTMS modiﬁed
mica substrate seen in panel (c) in ﬁgures 3.6 and 3.7, a diﬀerence in size is most clear. Both
AFM images show a corona formed around the hydrophobic cores and a blurry appearance. The
arrangement of the micelles implies that they may be deposited on top of each other or have
aggregated into larger structures; this is most obvious for 1 kDa CM. The 1 kDa CM looks to
have gathered in clots and what might be tightly packed micelles can also be observed. The
cross-section proﬁle for A in panel (c) ﬁgure 3.6 is representing a micelle, that do not have a
bright dot in the middle and the proﬁle shows a 2 nm height and very broad micelle. This
corresponds approximately to the observation done in panel (a) and (b). The cross-section
proﬁles for the two other observed 1 kDa CM are very broad and edgy, in comparison to the
observation for 6 kDa CM. The average height is the same for both, but the width of the cross-
sections are almost doubled for 1 kDa CM. The micelles are bound to collapse when deposited
on an attractive surface, but compared to the size observed in the NanoSight for 1 and 6 kDa
CM, the 6 kDa CM should be wider than 1 kDa CM, due to their size diﬀerence. However, if
the possibility of aggregation and the arrangement are taken into consideration, the width may
be explained. The cross-section line may also be longer than the observed structure, resulting
in a broader recorded width.
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As mentioned, the observations for 1 and 6 kDa CM contradict the observation done for
empty micelles. From the AFM images and height proﬁles for empty micelles (see ﬁgure 3.4), it
was implied that the empty micelles had a positively charged surface, and was attracted to the
freshly cleaved mica substrate, because of its negative charge. For the curcumin loaded micelles,
the AFM images imply that the micelles have a negatively charges and are more attractive to
the APTMS modiﬁed surface. In order to specify the exact surface charge of the individual
synthesised micelles, their zeta-potentials should have been measured. In the studies by Yang et
al. [46] and Liu et al. [55] they produced curcumin loaded micelles with zeta potential of 0.11
± 0.34 mV and - 0.41 ± 0.25 mV, respectively.
3.1.3 AFM images of APTMS modiﬁed mica substrates with untreated
micelles solution
The 6 kDa CM, synthesised as described in curcumin loaded micelles in section 2.2.1.1, are
deposited on an APTMS modiﬁed mica substrate by the method described in section 2.2.3.1.
The 6 kDa CM solution applied to the shown AFM images in panel (a) on the ﬁgures 3.8 and
3.9 have not been treated with ultrasound as described in section 2.2.3.1. The ﬁgures 3.8 and
3.9 show the untreated 6 kDa CM solution AFM images, with their height analysis from the
cross-sections proﬁles.
On ﬁgure 3.8 are a representation of the AFM image of as produced 6 kDa CM solution,
deposited on APTMS modiﬁed mica for 10 min, along with the respective height analysis.
Panel (a) shows the APTMS modiﬁed mica substrate and the deposited 6 kDa CM, with blue
lines representing cross-sections. The proﬁles for the cross-section can be seen on the graph in
panel (b). The proﬁles show the height and width of the structures. A height range of 7 - 22
nm and a width length of 120, 135, 220 and 225 nm. On panel (a) numerous structures are
observed at diﬀerent sizes, covering the entire APTMS modiﬁed mica substrate, which contains
the highest amount of observed structures on one sample.
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(a) (b)
Figure 3.8: AFM image of 6 kDa CM produced by loading micelles with curcumin as
described in section 2.2.1.1 along with their height analysis. Numbers decide the respective
cross-sections. Panel (a) represents the AFM image of 6 kDa CM without ultrasound treatment
and drop deposition on APTMS modiﬁed mica substrate for 10 min. Procedure can be found
in section 2.2.3.1. Panel (b) represents the cross-section proﬁles of the blue lines in panel (a).
Figure 3.9 shows the AFM image of untreated 6 kDa CM solution deposited on an APTMS
modiﬁed mica substrate for 5 min, along with the respective height analysis. On panel (a) the
APTMS modiﬁed mica substrate and the deposited 6 kDa CM are seen, along with blue lines
indicating cross-sections. The cross-section proﬁles are seen on the graph in panel (b), which
shows the structures height and width. The proﬁles show the cross-sections height range from
7 - 25 nm and a width range of 120 - 160 nm.
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(a) (b)
Figure 3.9: AFM image of 6 kDa CM produced by loading micelles white curcumin as
described in section 2.2.1.1 along with their height analysis. Numbers decide the respective
cross-sections. Panel (a) represents the AFM image of 6 kDa CM without ultrasound treatment
and drop deposited on APTMS modiﬁed mica substrate for 10 min. Procedure is described in
section 2.2.3.1. Panel (b) represents the cross-section proﬁles of the blue lines in panel (a).
Two of the cross-section proﬁles in panel (b) ﬁgure 3.9 show a decrease in height, indicating
a hole in the middle of the structures surface; this can be observed on panel (a). The decrease
in height can be observed as a black dot in the middle of a spherical orange structure.
The diﬀerence in deposition time before drying was investigated, by leaving the deposited
6 kDa CM solution not treated with ultrasound on APTMS modiﬁed mica substrates for 5
and 10 min. From the AFM images seen in panel (a) in ﬁgure 3.8 and 3.9 great diﬀerence
in concentration of micelles are observed. The AFM image of 6 kDa CM, with a depositing
time of 10 min (see panel (a) in ﬁgure 3.8), shows an arrangement of close arranged micelles
with diﬀerent sizes. Numerous micelles of identical sizes are observed, which corresponds well
with the size distribution analysis of 6 kDa CM not treated with ultrasound (see panel (b) in
ﬁgure3.3). The height and width of some of the diﬀerently sized micelles are seen in the cross-
section proﬁles, where the width gives a clear contrast to the size distribution. The AFM image
of 6 kDa CM with a deposition time of 5 min (see panel (a) in ﬁgure 3.9), shows less micelles
in comparison to a sample with 10 min deposition time. The micelle structures also appear to
be larger, which is a result of the diﬀering scale bar in each image. The scale bar for the two
AFM images, the 10 min depositing time in panel (a) ﬁgure 3.8 each have a scale bar of 600 nm,
while the AFM image for the 5 min depositing time in panel (a) ﬁgure 3.9 has a scale bar of 400
nm. Looking at the height proﬁle for in panel (b) ﬁgure 3.9, micelles with a collapsed core are
observed. The graph shows a decrease in the height proﬁle for two micelle structures. This is
further supported by the AFM image, where little bright dots with black dots in the middle are
observed. From the observation, the AFM images imply that the 10 min deposition time yields
large amounts of non-collapsed micelle structures, while 5 min deposition time results in fewer
micelle structures that collapse.
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3.1.4 AFM height distribution analysis
The following histograms in the ﬁgures 3.11 and 3.12 are graphic illustrations of the probability
distribution of the height and radius of micelles from 10 AFM images. The AFM images are
of 6 kDa CM, produced by loading micelles with curcumin, as described in section 2.2.1.1, and
depositing them on a freshly cleaved mica substrate, as described in section 2.2.3.1. The images
are processed by the WSxM software. Essentially, the images have their background subtracted
and then a ﬂooding function is used to estimate the average height and area of the micelles.
In panel (a) of ﬁgure 3.10 one of the AFM images is seen, with its background subtracted and
in panel (b) the ﬂooding function estimation of visible structures is shown, which yields the
average height and area of the visible structures.
(a) (b)
Figure 3.10: AFM image of 6 kDa CM produced by loading micelles with curcumin as
described in section 2.2.1.1. Panel (a) represents the AFM image of 6 kDa CM treated with
ultrasound, and drop deposited on a freshly cleaved mica substrate, see section 2.2.3.1. Panel
(b) represents a WSxM produced image with micelles identiﬁed.
The ﬂooding function presents the height and area in histograms, which can be extracted for
each AFM image and combined in the graphic illustrations seen in ﬁgures 3.11 and 3.12. The
AFM images used for the distribution analysis can be seen in Appendix A
The histogram seen in ﬁgure 3.11 represent the height distribution for the 10 AFM images
of 6 kDa CM deposited on freshly cleaved mica substrates. The histogram shows that most of
the detected micelles have an average height of 2.5 - 3 nm. Most of their heights lie between 1
- 3 nm and very few have a height from 3 nm and up.
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Figure 3.11: The histogram represents the average height distribution of 6 kDa CM deposited
on freshly cleaved mica substrates. Data obtained form 10 AFM images.
By assuming that all the observed structures are spherical, the radius was acquired from the
area estimation of the ﬂooding function and the area equation for a sphere. The histogram seen
in ﬁgure 3.12 represents the radius distribution analysis for all 10 AFM images of 6 kDa CM
deposited on freshly cleaved mica substrates. The histogram shows that a high amount of the
detected micelles have a radius of 50 - 60 nm.
Figure 3.12: The histogram represents the average radius distribution of 6 kDa CM deposited
on freshly cleaved mica substrates. Data obtained form 10 AFM images.
The height and radius distribution analysis, does not correspond to the size distribution seen
for 6 kDa CM in the NanoSight (see ﬁgure 3.3). Here the micelles have a maximum size of 142
nm and when comparing this to the radius distribution analysis, the micelle diameters mostly
lie in range of 50 - 60 nm, indicating that the micelles are smaller than estimated from the
NanoSights size distribution. Nonetheless, it is important to consider the amount of micelles
used for the analysis on both accounts. For the Nanosight analysis a larger concentration of
micelles is applied, while for the AFM images only a small portion of the deposited micelles were
analysed. For a more precise analysis, AFM images for the entire surface could be obtained.
The height distribution gives indications of the frequency of micelles on the substrate.
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3.2 Optical ﬂuorescence microscopy
Optical ﬂuorescence microscopy was conducted in 4 well borosilicate chambered slides. The
samples were produced by incubating cells with micelles and Hoechst dye as described in section
2.2.6. For the following images in ﬁgures 3.13, 3.14, 3.15, 3.16, 3.17 and 3.19 endocytosis
inhibitors are not used. Each image has a scale bar of 50 µm, unless any other condition is
shown or mentioned.
Figure 3.13 represent images from the optical ﬂuorescence microscope, where cell line CRL
2429 has been incubated with 1 kDa CM for 30 min. The images in panel (a) and (b) show
a single channel obtained with ﬁlters: panel (a) represent the DAPI channel, where the cells
nucleus is observed. Panel (b) represent the FITC channel, where the curcumin in the sample
is observed. Panel (c) shows both channels.
(a) (b) (c)
Figure 3.13: Fluorescence microscope images of CRL 2429 cells incubated with a 1 mg/mL
1 kDa CM solution for 30 min. Panel (a) represent the DAPI channel with an exposure time
of 100 ms. Panel (b) FITC channel with an exposure time of 200 ms and panel (c) shows both
channels, with the same exposure time as before.
The images show the CRL 2429 cells uptake of 1 kDa CM into the cells membrane. From the
single channel images, it is seen how curcumin is residing in all of the cell membrane interiors,
as well as where the cells nucleus is found. By combining the channels in panel (c), it can
be observed how the curcumin surrounds the nucleus, from the higher ﬂuorescence intensity of
curcumin. The FITC channel in panel (b) shows that curcumin covers the entirety of the cell,
including where the nucleus are seen in panel (c), with no changes in intensity. This may imply
that the inner membrane does not hinder the uptake of curcumin to the nucleus. Or it could be
the membrane behind the cell nucleus, since the FITC channel does not recognise the Hoescth
dye and neglects it. A 3D representation of a cell would estimate if the curcumin is residing in
the nucleus more clearly.
On ﬁgure 3.14 the images obtained from the optical ﬂuorescence microscope, for cell line U87
incubated with 1 kDa CM for 30 min are shown. The images in panels (a) and (b) indicate
which ﬁlter channel has been used; panel (a) represents the DAPI channel, thereby showing the
cells nucleus, where panel (b) illustrates curcumin in the sample with the FITC channel. Image
(c) illustrates both channels, to show the cells uptake of micelles.
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(a) (b) (c)
Figure 3.14: Fluorescence microscope images of U87 cells incubated with 1 mg/mL 1 kDa
CM solution for 30 min. Panel (a) represent the DAPI channel with an exposure time of
100 ms. Panel (b) FITC channel with an exposure time of 200 ms and panel (c) shows both
channels, with the same exposure time as before.
The images show the U87 cells uptake of 1 kDa CM into the cells membrane. The single
channel image seen in panel (b) shows the ﬂuorescence intensity of curcumin and at the same
time gives an indication of the U87 cells size. U87 cells do not adhere suﬃcient to the glass
surface of the slides, making them more likely to jump oﬀ the surface when washed. Therefore the
cells appear very small, compared to the standard observations of the star-shaped glioblastoma
cells (see section 1.5.1). The ﬂuorescence intensity also appears more enhanced than that of the
CRL 2429 cells, but their membranes are more visible and have the same enhanced intensity
around the nucleus, which implies that there is no apparent diﬀerence in intensity. This is
further illustrated in panel (c), where the channels are combined; it can be observed how the
curcumin surrounds the nucleus, again indicating that the inner membrane does not hinder the
uptake of curcumin in the nucleus.
Figure 3.15 illustrates the images obtained from the optical ﬂuorescence microscope of cell
line CRL 2429 incubated with 6 kDa CM for 30 min. The images in panels (a) and (b) show the
use of one ﬁlters channel: panel (a) shows the DAPI channel, panel (b) shows the FITC channel
and panel (c) shows a combination of the two channels.
(a) (b) (c)
Figure 3.15: Fluorescence microscope images of CRL 2429 cells incubated with 1 mg/mL 6
kDa CM solution for 30 min. Panel (a) represents the DAPI channel with an exposure time
of 100 ms. Panel (b) shows the FITC channel with an exposure time of 200 ms and panel (c)
shows both channels, with the same exposure time as before.
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On ﬁgure 3.16 three ﬂuorescence images of the cell line U87 incubated with 6 kDa CM for
30 min are shown. The images are obtained from the optical ﬂuorescence microscope, where
panels (a) and (b) have been obtained from a single ﬁlter channel: DAPI and FICT respectively.
Panel (a) illustrates the DAPI channel, where the cells nucleus can be seen and panel (b) shows
the FITC channel, where the cells uptake of curcumin is seen. Panel (c) shows both channels
together.
(a) (b) (c)
Figure 3.16: Fluorescence microscope images of U87 cells incubated with 1 mg/mL 6 kDa
CM solution for 30 min. Panel (a) represent the DAPI channel with an exposure time of
100 ms. Panel (b) FITC channel with an exposure time of 200 ms and panel (c) shows both
channels, with the same exposure time as before.
The ﬂuorescence images for both CRL 2429 and U87 cells incubated with 6 kDa CM,
show similar observations as for the cells incubated with 1 kDa CM (see ﬁgure 3.13 and
3.14). Curcumin shows a high ﬂuorescence intensity around the cells nucleus, implying that
the curcumin is being circulated towards the nucleus through the inner membrane, which does
not hinderer its path. Few cells are observed in the images compared to those seen for 1 kDa
CM, which depends on the region where the images are taken. The ﬂuorescent intensity shows
no signiﬁcant diﬀerence between 1 and 6 kDa CM; both micelles types seems to have a high
cellular uptake of curcumin.
Figure 3.17 represents the ﬂuorescent microscope images of cell line CRL 2429 incubated with
a free curcumin solution, with a concentration of 1 mg/mL for 30 min. The images in panels
(a) and (b) show a single channel obtained with ﬁlters: panel (a) represent the DAPI channel,
where the cells nucleus is observed. Panel (b) represent the FITC channel, where the curcumin
in the sample is observed. Panel (c) shows both channels.
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(a) (b) (c)
Figure 3.17: Fluorescence microscope images of CRL 2429 cells incubated with 1 mg/mL
free curcumin solution for 30 min. Panel (a) represent the DAPI channel with an exposure
time of 100 ms. Panel (b) FITC channel with an exposure time of 200 ms and panel (c) shows
both channels with the same exposure time as before.
The image shows the uptake of free curcumin by the CRL 2429 cells. From the single channel
images it is seen how a minimal concentration of curcumin is residing in all of the cell membrane
interiors, together with a representation of the cells nucleus. The channels are combined in panel
(c), where small curcumin aggregates become clearer, since they are positioned away from the
cells. The ﬂuorescent intensity of the curcumin aggregates are higher than the intensity of the
curcumin residing in the cells membrane.
Figure 3.18 represent an enlarged image of ﬁgure 3.17 with a scale bar of 20 µm, showing a
more precise illustration of the curcumin aggregates and the diﬀerence in ﬂuorescent intensity.
The images in panel (a) shows the FITC channel, where the curcumin is observed. From
this image it is possible to observe a lower ﬂuorescent intensity where the nuclei are placed,
when comparing to panel (b) where the DAPI and FITC channels are shown. This implies the
possibility that free curcumin, in comparison to curcumin micelles, may not penetrate the inner
membrane of CRL 2429 cells.
(a) (b)
Figure 3.18: Zoomed ﬂuorescent image of ﬁgure 3.17, indicated by the red square. Panel (a)
shows the FITC channel with an exposure time of 200 ms and panel (b) shows both channels,
with the same exposure time as before.
On ﬁgure 3.19 are the three ﬂuorescence microscope images of the cell line U87 incubated
with a 1 mg/mL free curcumin solution for 30 min. The images seen in panels (a) and (b) show
a single channel obtained with ﬁlters: panel (a) shows the application of the DAPI channel,
while panel (b) shows the FITC channel. A combination of the two channels is seen in panel
(c).
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(a) (b) (c)
Figure 3.19: Fluorescence microscope images of U87 cells incubated with 1 mg/mL 6 kDa
CM solution for 30 min. Panel (a) represent the DAPI channel with an exposure time of 100
ms. Panel (b) shows the FITC channel with an exposure time of 200 ms and panel (c) shows
both channels, with the same exposure time as before.
The images show the U87 cells uptake of free curcumin. From the single channel images, it
is shown that a very low concentration of curcumin resides in all of the cell membrane interiors,
together with a representation of the cells nucleus. The U87 cells small size, caused by their
tendency to jump oﬀ the surface when washed, makes their membrane very small. However, by
observation of panel (b), the low concentration becomes more apparent. Similar to CRL 2429
cells incubated with free curcumin, small curcumin aggregates are observed in panel (c), with
the combined channels. The ﬂuorescent intensity of the curcumin aggregates are higher than
the intensity of the curcumin residing in the cells membrane.
Figure 3.20 represent an enhanced imaged of ﬁgure 3.19, with a scale bar of 10 µm, showing
a more precise illustration of the curcumin aggregates and the diﬀerence in ﬂuorescent intensity.
The images in panel (a) shows the FITC channel, where the curcumin is observed. The images
illustrate diﬀerent sizes of curcumin aggregates, in combination with the low concentration of
curcumin uptake by the U87 cells. In panel (b) the DAPI channel is shown together with
the FITC channel, showing the location of the nucleus among the curcumin aggregates. In
comparison to ﬁgure 3.18 it appears that U87 inner membrane has been penetrated by the free
curcumin.
(a) (b)
Figure 3.20: Zoomed ﬂuorescent image of ﬁgure 3.19, indicated by the red square. Panel (a)
shows the FITC channel with an exposure time of 200 ms and panel (b) shows both channels,
with the same exposure time as before.
The overall observation from the ﬂuorescent microscope images is that the polymeric micelles
enhance the cellular uptake of curcumin, compared to free curcumin. The poor solubility of free
curcumin is clearly observed in the images, in the form of curcumin aggregates. No curcumin
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aggregates were observed for polymeric micelles. This all helps support the application of micelles
as a drug delivery system.
3.2.1 Cross sections
The following 3D ﬂuorescence microscope images in ﬁgures 3.21 and 3.22 are each a construction
of 40 z-stacked layers obtained with the DAPI, FITC and DsRed ﬁlter channels, with diﬀerent
exposure times. The scale bars for each image are 20 µm. The samples are produced by
incubating cells with micelles and Hoechst dye as described in section 2.2.6, without incubation
with endocytosis inhibitors.
The 3D images presented in ﬁgure 3.21 show the 1 kDa CM solution incubated with CRL
2429 and U87 for 30 min. Panel (a) shows the CRL 2429 cells with the DAPI and FITC channels.
In addition three blue arrows can be seen. These arrows all point to the same micelle, seen from
diﬀerent angles.
(a) (b)
Figure 3.21: 3D ﬂuorescent microscope images, consisting of 40 z-stacked layers, showing
CRL 2429 and U87 cells incubated with a 1 mg/mL 1 kDa CM solution for 30 min. The
images are obtained by using the DAPI and FITC channels, and the exposure time is diﬀerent
for each image. Panel (a) show the 3D representation of CRL 2429 cells, with an exposure
time of 6 ms and 600 ms. Panel (b) show the 3D representation of U87 cells, with an exposure
time of 6 ms and 850 ms. The blue arrows points to the cross section of the image, while the
white arrows points to a vesicle in the cells interior.
In panel (b) cell line U87 incubated with 1 kDa CM is seen with the DAPI and FITC
channels. Furthermore, three blue and one white arrow are shown on the image, to highlight
the cross-section point and a vesicle in the cells interior, respectively.
The 3D images presented in ﬁgure 3.21 shows the 6 kDa CM solution incubated with CRL
2429 and U87 for 30 min. Panel (a) shows the CRL 2429 cells with the DAPI and DsRed
channels. In addition three blue and one white arrow have been inserted. The blue arrows
indicate the point of cross-section of the image, while the white arrow illustrates a vesicle with
curcumin in the cells interior.
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(a) (b)
Figure 3.22: 3D ﬂuorescent microscope images, consisting of 40 z-stacked layers, showing
CRL 2429 and U87 cells incubated with a 1 mg/mL 1 kDa CM solution for 30 min. The
images are obtained by using the DAPI and DsRed channels, with exposure times of 100 ms
and 700 ms. Panel (a) show the 3D representation of CRL 2429 cells. Panel (b) show the 3D
representation of U87 cells. The blue arrows points to the cross section of the image, while the
white arrow points to a vesicle in the cells interior.
In panel (b) cell line U87 incubated with 6 kDa CM is observed with the DAPI and DsRed
channels. In addition three blue and one white arrow are shown on the image, to highlight the
cross-section point and a vesicle at the border to the cells nucleus, respectively.
The U87 images are not optimal, because of their small size and quality, but they eﬃciently
show the eﬀect of the curcumin cellular uptake. Each image shows that the curcumin has been
distributed uniformly throughout the cell membranes, while the cross-section point indicates
that some of the curcumin has reached the nucleus. In panel (a) ﬁgure 3.22, what looks to be
a curcumin vesicle in the CRL 2429 cell nucleus is observed at the cross-section point. Panel
(a) in ﬁgure 3.21 shows no signs of curcumin in its nucleus, which is also observed for U87
cells incubated with 1 kDa curcumin. Panel (b) in ﬁgure 3.22 may illustrate a vesicle in the
nucleus, but the quality of the images makes it diﬃcult to determine. If this observation is true,
it implies that 6 kDa CM have the ability to transport curcumin to the cell nucleus. Further
studies of this observation is needed, to make a more deﬁnite determination, such as more optimal
and additionally images of this observation. There is the possibility, that the curcumin vesicle
observed is a reﬂection. In the cell membrane on ﬁgure 3.22 panel (a), a spherical aggregate is
observed, which may be a vesicle containing curcumin, thereby showing the endocytosis process
of the CRL 2429 cell. The U87 cells in both ﬁgures show, what is thought to be an empty vesicle
in their membrane and close to their nucleus, because of the non-exciting ﬂuorescent intensity.
It can be a result of the image quality or molecules in the PBS medium, which reside above the
cells and interfere with the images.
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3.2.2 Endocytosis routes
In order to investigate the endocytosis routes for the micelles, experiments have been conducted
with various endocytosis inhibitors, dynasore hydrate and worthmaninn, to hinder some
pathways into the cells. In the following images comparisons between cells incubated with
and without endocytosis inhibitors are shown for both cell lines. The samples are produced by
incubating cells with micelles and Hoechst dye as described in section 2.2.6.
3.2.2.1 Cell line U87 with and without endocytosis inhibitors
On ﬁgure 3.23 three ﬂuorescent microscope images of U87 are shown, incubated with 1 kDa CM,
worthmaninn and dynasore for 30 min. Panel (a) shows the sample incubated only with 1 kDa
CM, with the DAPI and FITC channels. In panel (b) the sample pre-incubated with dynasore
is seen, also with the DAPI and FITC channels.
(a) (b)
(c)
Figure 3.23: Fluorescence microscope images of U87 cells incubated with 1 mg/mL 1 kDa
CM solution, worthmaninn and dynasore for 30 min. Panel (a) shows the sample without any
inhibitors, panel (b) shows the sample pre-incubated with dynasore and panel (c) the sample
pre-incubated with worthmaninn. The images are obtained with DAPI and FITC channels,
with the exposure times of 100 and 200 ms.
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On the last panel (c) the sample pre-incubated with 1 kDa CM and worthmaninn is illustrated.
Here are the DAPI and FITC channels used. As mentioned previously, U87 cells do not adhere
suﬃciently to the glass surface of the slides, making them more likely to jump oﬀ the surface
when washed, explaining the few and small cells observed in the images. Additionally, the cells
exhibit no diﬀerence in cellular uptake of curcumin, when pre-incubated with the endocytic
inhibitor dynasore and receptor mediated endocytosis inhibitor Worthmaninn. The ﬂuorescence
intensity is similar for all the images.
Figure 3.24 represents three ﬂuorescence microscope images of cell line U87 incubated with
a 6 kDa CM solution, with and without the inhibitors dynasore and worthmaninn. Panel (a)
shows the incubated cell without inhibitors and panel (b) shows the cells pre-incubated with




Figure 3.24: Fluorescence microscope images of U87 cells incubated with 1 mg/mL 6 kDa
CM solution, worthmaninn and dynasore for 30 min. Panel (a) shows the sample without
any inhibitors, panel (b) show the sample pre-incubated with dynasore and panel (c) the
sample pre-incubated with worthmaninn. The images are obtained with the DAPI and DsRed
channels, with an exposure times of 15 and 950 ms for (a) and (b), while (c) is obtained with
the DAPI and FITC channels, with the exposure times 100 and 200 ms.
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In panel (c) the cells pre-incubated with worthmaninn are seen; the image was obtained with
the DAPI and FITC channels. The amount of cells seen in each image diﬀers for each sample.
In panels (a) and (b) the U87 cells have their characteristic star-shape, showing that the cells
are still adhering to the slides surface. This results in more cells, since they are not washed
away during the sample production. In the panels, there are areas with high concentrations
of curcumin, which can be representative of a micelle core or curcumin residue from the 6
kDa CM solution, even though it has been centrifuged. The curcumin structures resemble the
curcumin aggregate seen in ﬁgure 3.19, where the cells were incubated with free curcumin.
Furthermore what appeasers to be reﬂections are observed in all the images, which can be from
the attached chambers, where the light is reﬂected back on the slides surface. Nevertheless, the
cells exhibit no diﬀerence in cellular uptake of curcumin when pre-incubated with the endocytic
inhibitor dynasore and receptor mediated endocytosis inhibitor Worthmaninn, matching the
result obtained from 1 kDa CM.
3.2.2.2 Cell line CRL 2429 with and without endocytosis inhibitors
On ﬁgure 3.25 three ﬂuorescent microscope images of cell line CRL 2429, incubated with a 1
kDa CM solution with and without the endocytosis inhibitors dynasore and worthmaninn, are
illustrated. Panel (a) represents the cells only incubated with 6 kDa CM, with the DAPI and
FITC channels. In panel (b) the cells which have been pre-incubated with dynasore can be seen,
with the DAPI and FITC channels.
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(a) (b)
(c)
Figure 3.25: Fluorescence microscope images of CRL 2429 cells incubated with a 1 mg/mL
1 kDa CM solution, containing worthmaninn and dynasore for 30 min. Panel (a) shows the
sample without any inhibitors, panel (b) shows the sample pre-incubated with dynasore and
panel (c) the sample pre-incubated with worthmaninn. The images are obtained with DAPI
and FITC channels, with the exposure times of 100 and 200 ms for (a) and (b), while (c) is
obtained with the DAPI and DsRed channels, with the exposure time 100 ms and 1 s.
Panel (c) shows the cells pre-incubated with the inhibitor worthmaninn, with the DAPI and
DsRed channels. A large diﬀerence in the amount of cells can be seen between image (a) and
(b), as compared to image (c). The diﬀerence in cell concentration can be the cause of diﬀerent
obtained conﬂuence for each sample, or the image region of the sample. Comparable to the
U87 cells, the CRL 2429 cells do not exhibit diﬀerence in cellular uptake of curcumin when
pre-incubated with inhibitors. The images do show many presumed curcumin vesicles in the
cells membrane in all the samples. Additionally, there is a high diﬀerence in exposure time for
the FITC and DsRed channels, which is provoked by the sample curcumins ﬂuorescent intensity
which diminishes over time. Exposure to light will also inﬂuence the intensity of the ﬂuorescent
dyes.
Figure 3.26 represents three ﬂuorescence microscope images of CRL 2429 cells incubated with
a 6 kDa CM solution, with and without the endocytosis inhibitors dynasore and worthmaninn.
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In panel (a) the cells incubated only with 6 kDa CM are seen, while panel (b) shows the cells




Figure 3.26: Fluorescence microscope images of CRL 2429 cells incubated with a 1 mg/mL 6
kDa CM solution, worthmaninn and dynasore for 30 min. Panel (a) shows the sample without
any inhibitors, panel (b) shows the sample pre-incubated with dynasore and panel (c) the
sample pre-incubated with worthmaninn. The images are obtained with DAPI and DsRed
channels, with the exposure times of 100 and 700 ms for panel (a) and with a exposure times
of 100 ms and 1 s for panel (b) and (c).
In panel (c) the cells pre-incubated with worthmaninn are shown. The image has, like the
others, been obtained with the DAPI and DsRed channels. A small diﬀerence in the amount
of CRL 2429 cells is seen between each image. Again the cells exhibited no diﬀerence in their
cellular uptake of curcumin when pre-incubated with the endocytosis inhibitors. Dynasore has
been shown to inhibit the cellular uptake, depending on dynamic functions such as Clathrin-
dependent and Cavolin-dependent pinocytosis. [73] Fluorescent microscopy is not the most
optimal way to estimate inhibited cellular uptake of cells; therefore further investigation is
necessary to determine dynasore inhibiting ability towards the synthesised micelles.
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3.3 Cytotoxicity assay
The inter-cellular drug delivery release of curcumin and empty micelles is investigated using a
multi-mode plate reader and a CytoTox-ONETM assay kit, as described in section 2.2.5. Light
micro-graphs from before and after the 24 h incubation period, with diﬀerent micelles types and
concentrations, can be seen in Appendix B. The multi-mode plate reader measures the release
of LDH from cells with a damaged membrane, using an excitation wavelength of 560 nm and an
emission wavelength of 590 nm. The standard deviation values are based on 9 data points for
1 kDa and 6 kDa CM as well as for the empty micelles, whereas it is based on 3 - 4 points for
free curcumin.
3.3.1 Curcumin loaded micelles
3.3.1.1 Cell line CRL 2429
Figure 3.27 shows the results from the cytotoxicity assay using CRL 2429 and 1 kDa and 6
kDa CM at concentrations of 1, 0.1, 0.01 and 0.001 mg/mL, as well as free curcumin with a
concentration of 1 mg/mL. On the graph three data sets can be seen, where the cells have been
incubated with free curcumin, 1 kDa CM and 6 kDa CM respectively, for 24 hours. The 6 kDa
CM curve starts at ∼5% mortality and decreases slightly to ∼2%, after which it continues to
increase from ∼9% to ∼60% mortality.
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Figure 3.27: The graph represents the mortality % for CRL 2429 cells after 24 hours
incubation with diﬀerent concentrations of 1 and 6 kDa CM, as well as free curcumin with
a concentration of 1 mg/mL. Each data point is an average of 9 measurements for 1 kDa and




The 1 kDa CM curve starts at ∼3% mortality and remains there until the concentration
reaches 0.01 mg/mL. Afterwards the mortality increases to ∼15% and continues up to ∼92%.
The standard deviation values increase with the concentration of 1 and 6 kDa CM. For free
curcumin the mortality % is at ∼20% for a solution of 1 mg/mL.
Both 1 kDa and 6 kDa CM show an exponential curve, where 1 kDa remains higher in
mortality % than 6 kDa CM. CRL 2429 are skin cells, making them a part of the human body
frame structure, placing them in the healthy cell category. The high mortality of ∼92% for 1
kDa CM are therefore far from an ideal result, which also can be stated for 6 kDa CM mortality
of ∼60%. Both mortality % are obtained at a concentration of 1 mg/mL, indicating that the
concentration has to be reduced. A general overview of the graph shows that the cytotoxic
activity increases with an increase in concentration, and that curcumin loaded in 1 and 6 kDa
PVP polymers enhances the cytotoxic activity of curcumin, as compared to the free curcumin
solution at 1 mg/mL.
In ﬁgure 3.28 a concentration deduction of the cytotoxicity assay results for cell line CRL
2429 is shown, with 1 and 6 kDa CM and free curcumin at concentrations of 0.2, 0.4, 0.6 and
0.8 mg/mL. On the graph three data sets can be seen, where the cells have been incubated with
free curcumin, 1 kDa CM and 6 kDa CM, respectively for 24 hours. The curve for 6 kDa CM
shows an adequate linear increase in mortality %, with an increase from ∼7% to ∼36%. Free
curcumin shows a more exponential increase from ∼2% to ∼16% mortality. Standard deviation
values for free curcumin increase with the increase in concentration.
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Figure 3.28: The graph represent the mortality % of CRL 2429 cells after 24 hours of
incubation with diﬀerent concentrations; 0.2, 0.4, 0.6 and 0.8 mg/mL of free curcumin, 1 kDa
and 6 kDa CM. Each data point is an average of 9 measurements for 1 and 6 kDa CM, while
it is an average of 3 measurements for free curcumin.
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For 1 kDa CM, a curved line is seen, with a starting point at ∼23% mortality, followed by a
decrease to ∼ 19%. The curve then increases slightly to ∼23% and ends at ∼33%. Both 1 and
6 kDa CM standard deviation values diﬀer for each point.
The mortality for both 1 and 6 kDa has decreased to below 50% for the highest concentration
at 0.8 mg/mL, when compared to ﬁgure 3.27. A full curve is seen for free curcumin and its
cytotoxic activity also rises with an increase in concentration. The 6 kDa CM curve is shown
to ﬁt well with the curve seen in ﬁgure 3.27, whereas 1 kDa CM seems higher than previously
observed. The standard deviation for 1 kDa CM is very high for the entire curve, which can be
caused by its poor ability to dissolve properly. The pipetting and the amount of cells in the two
individual experiments can have an eﬀect on the observed result. The cytotoxic activity for 1
and 6 kDa CM is very dependent on concentration, but even with the high mortality %, 6 kDa
CM appears to be less cytotoxic towards CRL 2429 than 1 kDa CM.
3.3.1.2 Cell line U87
Figure 3.29 shows the results for the cytotoxicity assay, with U87 cells incubated for 24 h, with
1 and 6 kDa CM at concentrations of 1, 0.1, 0.01 and 0.001 mg/mL, as well as free curcumin
with a concentration of 1 mg/mL. On the graph three data set can be seen, where the cells have
been incubated with either free curcumin, 1 kDa CM or 6 kDa CM. The curve for 6 kDa CM
shows a small increase from ∼4% mortality to ∼7% followed by a slight decrease to ∼6% for the
concentrations 0.001, 0.01 and 0.1 mg/mL. Between the concentrations of 0.1 and 1 mg/mL a
rapid increase in mortality % is seen for 6 kDa CM, reaching up to ∼46%.
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Figure 3.29: The graph represent the mortality % of U87 cells after a 24 hour incubation with
diﬀerent concentrations: 0.001, 0.01, 0.1 and 1 mg/mL of 1 kDa and 6 kDa CM, as well as free
curcumin with a concentration of 1 mg/mL. Each data point is an average of 9 measurement
for 1 kDa and 6 kDa CM, while it is an average of 3 measurement for free curcumin.
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The curve for 1 kDa CM shows a constant mortality % of ∼4% for the lowest concentrations:
0.001, 0.01 and 0.1 mg/mL. A rapid increase is seen at 1 mg/mL, where the mortality is at
∼39%. The standard deviation values for 1 kDa CM are only seen for 0.1 and 1 mg/mL. For
free curcumin, the mortality % is at ∼6% for a solution of 1 mg/mL.
Both 1 and 6 kDa CM are shown to have an almost constant cytotoxic activity at the lowest
concentrations, where 6 kDa CM has a slightly higher mortality % than 1 kDa CM. Since U87
are brain tissue cells aﬀected with glioblastoma, these are categorised as tumour cells; therefore
an inhibition eﬀect on the cells is wanted. The inhibition eﬀect is seen from the mortality %.
The high mortality of ∼46% for 6 kDa CM is therefore an adequate result. When incorporating
the high mortality % for 6 kDa CM from ﬁgure 3.27, the situation becomes less favourable.
This comparison shows that 1 mg/mL of 6 kDa CM may inhibit the tumour growth with 50%,
but the probability of damaging or killing the surrounding cells are at 60%. For 1 kDa CM
the comparison would imply an inhibition of 40% and a probability of damaging or killing the
surrounding cell of 90%, thereby making 6 kDa CM the more favourable of the two synthesised
micelles. This again indicates that the concentration has to be reduced. As seen in ﬁgure 3.27,
the curcumin loaded 1 and 6 kDa PVP polymer enhances the activity of curcumin.
On ﬁgure 3.30 a concentration deduction for the cytotoxicity assay results for cell line U87
is shown for diﬀerent concentration: 0.2, 0.4, 0.6 and 0.8 mg/mL for 1 and 6 kDa CM, and
free curcumin. On the graph three data sets can be seen, where the cells have been incubated
with free curcumin, 1 and 6 kDa CM respectively. The curve for free curcumin shows an almost
constant mortality % of ∼2% between concentration of 0.2 - 0.4 mg/mL, followed by a slight
decrease to 1% at 0.6 mg/mL. At concentrations of 0.8 mg/mL, the curve increases to its highest
mortality % at ∼6%. Here the largest standard deviation is seen for free curcumin. The 1 kDa
CM curve starts at its highest mortality % at ∼57% at the lowest concentration of 0.2 mg/mL,
and decreases to ∼40% at a concentration of 0.4 mg/mL. The mortality increases further at
higher concentrations and ends at ∼50% mortality. The standard deviation values for 1 kDa
CM at the high concentrations are almost constant. The highest deviation value is seen at 0.2
mg/mL.
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Figure 3.30: The graph represents the mortality % of U87 cells after 24 hours incubation
with diﬀerent concentrations: 0.2, 0.4, 0.6 and 0.8 mg/mL of free curcumin, 1 and 6 kDa CM
respectively. Each data point is an average of 9 measurement for 1 kDa and 6 kDa CM, while
it is an average of 3 measurement for free curcumin.
For 6 kDa CM, a small mortality is seen at ∼4% for a concentration of 0.2 mg/mL, which
increases to ∼11%. The curve decreases a little at 0.6 mg/mL to ∼10% mortality, followed by a
rapid increase to ∼60% mortality. The standard deviation values diﬀer for each point, with the
highest at 0.8 mg/mL.
In parallel to the observation from the deduction in concentration for CRL 2429 (see ﬁgure
3.28), the mortality for U87 incubated with 6 kDa CM has decreased at the lower concentrations,
and increased at the high concentration of 0.8 mg/mL. At 0.8 mg/mL 6 kDa CM has reached
a mortality of 60%, in comparison to the 46% in ﬁgure 3.29; the same can be seen for 1 kDa
CM. This diﬀerence is caused by the individual experiments; the plating of the cells and their
stage of conﬂuence can vary, causing diﬀerences in the amount and viability of cells between
experiments. In order to avoid this inﬂuence on the results, the two experiments should have
been performed on the same plate. Another area that may inﬂuence the results is the pipetting.
Each well is pipetted manually, which can cause a deviation, since one does not pipette the same
way twice. Again a high standard deviation is observed for 1 kDa CM for the entire curve. This
can be caused by the previously mentioned conditions, and its observed poor ability to dissolve.
6 kDa CM is shown to increase more slowly in cytotoxic activity for concentrations of 0.2, 0.4
and 0.6 mg/mL, where it in ﬁgure 3.28 increases linearly, making it diﬃcult to determine an
optimal concentration, that damage less healthy cells than tumour cells.
From the observations done in the above ﬁgures 3.27, 3.28, 3.29 and 3.30 it can be deduced
that 6 kDa CM has a lower cytotoxic activity when incubated with CRL 2429 than 1 kDa
CM, making it favourable by not damaging healthy cells and still retaining a high cytotoxicity
when incubated with tumour cells. All the graphs show that curcumin loaded in PVP polymer
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increase the cytotoxic activity of curcumin by more than what is observed for free curcumin.
This corresponds to the observations seen in the ﬂuorescent images, that the cellular uptake of
curcumin enhances when encapsulate in PVP polymer. The same eﬀect was seen in the study
by Yang et al. [46] and Liu et al. [55].
3.3.2 Empty micelles
3.3.2.1 Cell line U87
Figure 3.31 shows the results from the cytotoxicity assay using U87 incubated with 6 kDa empty
micelles and free curcumin at concentrations of 1, 0.1, 0.01 and 0.001 mg/mL. On the graph
two data set can be seen, where the cell have been incubated with free curcumin and 6 kDa
empty micelles. The curve for free curcumin shows a starting point of ∼7% mortality, which
then increases to ∼27%. The curve then decreases to a mortality of ∼8% for concentrations
0.1 mg/mL. At a concentration of 1 mg/mL it has increased to ∼18% mortality. The standard
deviation for free curcumin, which is most apparent, is located at 0.01 mg/mL.
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Figure 3.31: The graph represent the mortality % of U87 cells after 24 hours incubation with
diﬀerent concentrations: 0.001, 0.01, 0.1 and 1 mg/mL of free curcumin and empty micelles.
Each data point is an average of 9 measurement for empty micelles, while it is an average of 3
measurement for free curcumin.
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For 6 kDa empty micelles, the curve starts at ∼11% mortality and decreases to ∼3% for a
concentration 0.01 mg/mL. At a concentration of 0.1 mg/mL an increase to ∼8% mortality is
seen, after which it increases rapidly to 97% mortality. The standard deviation for 6 kDa empty
micelles is only presented at 0.001 mg/mL and 0.1 mg/mL.
The empty micelles were synthesised using 6 kDa PVP polymer, because of its low cytotoxic
activity towards CRL 2429, seen in the result of the cytotoxicity experiment in section 3.3.1.
The empty micelles incubated with U87 cells illustrate an increase in cytotoxic activity, along
with an increase in micelle concentration, comparable to the observations seen on the graphs
for curcumin loaded micelles (see ﬁgure 3.29). The lower concentration maintains a molarity
around 10%, corresponding to previous observations for U87 cells incubated with 6 kDa CM
as seen on ﬁgure 3.29. The mortality of 97% for 1 mg/mL empty micelles incubated with U87
cells is very high, when compared to the results for 1 and 6 kDa CM observed in ﬁgure 3.29.
The empty micelles have a cytotoxic activity almost twice as high. The curve for free curcumin
remains at a mortality below 20%, with the exception of the sample with a concentration 0.01 of
mg/mL, where the mortality is at 27%. The cause for the high mortality and standard deviation
observed at 0.01 mg/mL, can be attributed to the poor solubility of curcumin in aqueous media.
The DMEM 10% FBS 1% growth medium has a pH value of 7.4, making it a basic environment
where curcumin is unstable and diﬃcult to dissolve. Furthermore, a colour change in the media
is an indication of chance in pH, meaning that the media has a higher pH when it appears dark
red/purple and low pH at a yellow/brighter colour. The individual pipetting of the well can
additionally have an inﬂuence on the high deviation observed.
The mortality for the empty micelles can be a result of their small and unstable structure.
As previous discussed the empty micelles might possibly detach into monomers and aggregates
when dissolved. The empty micelles, and subsequently the monomers and aggregates, can,
because of their small size, easily diﬀuse into the cell, without being eﬀected by the force at
the nano-bio interface. The high concentration of empty micelles, might have damaged the cells
membrane through numerous penetrations, resulting in a high mortality %, since the cytotoxicity
assay measures LDH release from damaged cells. To investigate this implication further, other
cytotoxicity assays could have been used to give a more precise estimation of all the micelles
cytotoxic activity.
Figure 3.32 shows the concentration deduction results from the cytotoxicity assay using U87
cells incubated with 6 kDa empty micelles and free curcumin at diﬀerent concentrations: 0.2,
0.4, 0.6 and 0.8 mg/mL. The curve for free curcumin shows an almost constant percentage of
mortality. It has a constant mortality of ∼2% between concentration 0.2 - 0.4 mg/mL, after
which a slight decrease to 1% at 0.6 mg/mL is seen. At concentration 0.8 mg/mL, the curve
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Figure 3.32: The graphs represent the mortality % of U87 cells after 24 hours of incubation
with diﬀerent concentrations: 0.2, 0.4, 0.6 and 0.8 mg/mL of free curcumin and empty micelles.
Each data point is an average of 9 measurement for empty micelles, while it is an average of 3
measurement for free curcumin.
For 6 kDa empty micelles, a constant mortality of ∼16% is seen, between concentrations of
0.2 and 0.4 mg/mL. A rapid increase in mortality is shown at a concentration of 0.6 mg/mL,
where it increases to ∼68%. The mortality continues to increase to a ﬁnal value of ∼99%. The
standard deviation diﬀers for empty micelles; the largest is seen at a concentration of 0.6 mg/mL.
From the reduced concentration in ﬁgure 3.32, it is seen that the empty micelles almost
linearly ﬁt between the concentrations of 0.1 and 1 mg/mL in ﬁgure 3.31. The mortality of
99% is higher than observed in ﬁgure 3.31, possibly as a result of pipetting and dissolving the
diﬀerent concentrations. In contrast to the previous cytotoxicity assay experiments, ﬁgure 3.32
and ﬁgure 3.31 are performed on the same multiwell-plate, to prevent the inﬂuence of the stage
of conﬂuence between the samples. It cannot be avoided completely, only to some extent. The
pipetting and the dissolving of the concentration are therefore more likely to be the cause of
the observed deviations. The cytotoxic activity increases with the empty micelle concentration.
The free curcumin remains at a mortality around 2%.
3.3.2.2 Cell line CRL 2429
Figure 3.33 shows the results from the cytotoxicity assay of CRL 2449 incubated with 6 kDa
empty micelles and free curcumin at concentrations of 1, 0.1, 0.01 and 0.001 mg/mL. The curve
for free curcumin starts with a mortality of ∼1%, followed by a slight decrease to ∼0%. At a
concentration of 0.1 mg/mL, the curve increases to a mortality of ∼4% and decreases again to
∼3% at 1 mg/mL. The standard deviation values are very low for free curcumin, the highest
being at 0.1 mg/mL.
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Figure 3.33: The graph represent the mortality % of CRL 2429 cells after 24 hours incubation
with diﬀerent concentrations: 0.001, 0.01, 0.1 and 1 mg/mL of free curcumin and empty
micelles. Each data point is an average of 9 measurement for empty micelles, while it is an
average of 3 measurement for free curcumin.
For the 6 kDa empty micelles, the curve shows an almost constant mortality percentage at
∼1% for the lowest concentrations: 0.001, 0.01 and 0.1 mg/mL. Between concentrations 0.1 and
1 mg/mL a rapid increase to ∼56% mortality is seen. The highest standard deviation seen for
6 kDa empty micelles is at 1 mg/mL.
The 6 kDa empty micelles incubated with CRL 2429 cells exhibit a constant cytotoxic activity
for the low concentrations, which are low in comparison to ﬁgure 3.31 and ﬁgure 3.27. The
highest mortality for the empty micelles is 56%, resulting in a lower cytotoxic activity in CRL
2429 cells, compared to U87 cells, with almost 40%. Therefore, the empty micelles have as little
cytotoxic activity as a drug delivery carrier. The same was concluded in the study by Yang et al.
[46], whose experiments spanned over 48 hours. Free curcumin, as previously seen, maintains its
low cytotoxic activity below 10%. It can be concluded that the individual pipetting is probably
the cause of the standard deviation observed.
As previously mentioned, the concentration of the micelles is investigated further, by looking
at some concentrations between 0.1 and 1 mg/mL. This reduction of the concentration is seen in
ﬁgure 3.34. Figure 3.34 shows the results from the cytotoxicity assay using CRL 2429 cells and
6 kDa empty micelles at concentrations of 0.2, 0.4, 0.6 and 0.8 mg/mL, as well as free curcumin.
On the graph, two data set can be seen, where the cells have been incubated with free curcumin
and 6 kDa empty micelles for 24 h. The 6 kDa empty micelles curve has a starting point at
∼7% mortality, followed by a somewhat linear increase. At a concentration of 0.4 mg/mL the
mortality has reached ∼18%, and increases further to ∼27% at 0.6 mg/mL. The ﬁnal increase
leaves the mortality at ∼51%. The standard deviation is large and diﬀerent for each point.
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Figure 3.34: The graph represent the mortality % of CRL 2429 cells after 24 hours incubation
with diﬀerent concentrations: 0.2, 0.4, 0.6 and 0.8 mg/mL of free curcumin and empty micelles.
Each data point is an average of 9 measurement for empty micelles, while it is an average of 3
measurement for free curcumin.
The curve for free curcumin has an exponential increase for each data point, with a start
at ∼2% mortality at a concentration of 0.2 mg/mL. It then increases to ∼4% at 0.4 mg/mL
and further to ∼6% at 0.6 mg/mL, before it ends at ∼16% mortality. The standard deviation
increases with the increase in concentration.
The empty micelle concentrations between 0.1 and 1 mg/mL are similar to ﬁgure 3.32, with
a lower cytotoxic activity. The empty micelles have a linear mortality increase, which increases
with the concentration of micelles. The ﬁnal mortality of the micelles in ﬁgure 3.34 is a little
lower than observed for 1 mg/mL in ﬁgure 3.33 and rises slightly at 0.2 mg/mL, making the curve
follow the curve for the empty micelles in ﬁgure 3.33. In contrast to the previous cytotoxicity
Assay, experiments seen in ﬁgure 3.34 and ﬁgure 3.33 were performed on the same multiwell-
plate, to prevent the inﬂuence of the stage of conﬂuence. High standard deviation values are
observed for all the point in the empty micelles curve, which is as previously stated most likely
caused by pipetting errors and dissolving errors. The free curcumin shows a little increase in
cytotoxic activity, but remains below 20%.
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3.4 Flow cytometric analysis
In order to further investigate the endocytosis routes for the micelles, experiments have been
conducted with a ﬂow cytometer and two endocytosis inhibitors: dynasore hydrate and sodium
azide. The seeded cells were pre-incubated with the inhibitors for a speciﬁc time, followed by
incubation with 6 kDa CM for 30 min, before being trypsinated, the process of which is described
in section 2.2.7. In the following ﬁgures 3.35, 3.36, 3.37 and 3.38 the data collected from the
ﬂow cytometer is presented as two-dimensional dot plots and a one-dimensional graph.
In ﬁgure 3.35 the two-dimensional dot-plot of the ﬂow cytometer data for cell line CRL
2429 is shown. The plot represents the distribution of cells based upon their relative size and
internal complexity. The relative size is represent by the axis FSC and internal complexity by
the axis SSC. Figure 3.35 shows an overlay of all the samples, to identify the cells based on their
morphology. An area of the cells has been outlined by the ellipses and is called P1; this area is
used for further investigation. The remaining cells observed in the left corner are presumed to
be cell residues, particles from the media or other residues in the samples. Each sample has its
own colour to separate them.
Figure 3.35: The 2D dot-plot represents the distribution of CRL 2429 cells based upon their
relative size and internal complexity. The CRL 2429 cells have been pre-incubated with the
endocytosis inhibitor dynasore at 37◦C and sodium azide at 4 and 37◦C for 30 min. Afterwards
the samples have been incubated with 1 mg/mL 6 kDa CM for 30 min (see section 2.2.7). Each
sample is illustrated with their own colour. An area has been outlined and is referred to as
P1, which is used for further investigation.
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In ﬁgure 3.36 the two-dimensional dot-plot for cell line U87 is observed. The plot is an overlay
of all the U87 samples, used to identify cells based on their morphology. An area of interest
has been outlined by the ellipses and is called P3; this area of cells will be used for further
examination. The cells left out of the ellipses are considered cell residues, particles from the
media or other residues in the samples. Each sample has their own colour to diﬀerentiate them.
Figure 3.36: The 2D dot-plot represents the distribution of U87 cells based upon their relative
size and internal complexity. The U87 cells have been pre-incubated with the endocytosis
inhibitor dynasore at 37◦C and sodium azide at 4 and 37◦C for 30 min. Afterwards have the
samples been incubated with 0.5 mg/mL 6 kDa CM for 30 min (see section 2.2.7). Each sample
has been illustrated with their own colour. An area has been outlined and is referred to as P3,
which is used for further investigation.
When comparing the two dot-plots, a small diﬀerence in complexity is observed between
CRL 2429 and U87. The U87 cells show a higher internal complexity than CRL 2429, which is
probably because of its star-shaped structure. CRL 2429 have a more elongated circular shape,
which does not result in much side scattering.
From the cells in outlined areas P1 and P3 in ﬁgure 3.35 and 3.36, the presence of curcumin in
the cells is determined. The presence of curcumin in the cell lines is shown from the ﬂuorescent
intensity distribution in the cells, in relation to the counted cells, which are plotted in a
histogram. The histograms represent the ﬂuorescent intensity distribution of the cells, and
each histogram is an overlay of all the samples. The histogram overlays are seen in ﬁgures 3.37
and 3.38.
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In ﬁgure 3.37 the ﬂuorescent intensity of the CRL 2429 cells is illustrated, in relation to the
counted cells. From ﬁgure 3.37 it is seen that the control sample has a lower intensity than the
samples incubated with curcumin. The remaining sample that has been incubated at a diﬀerent
temperature and with diﬀerent inhibitors show no signiﬁcant changes in intensity. There is a
small diﬀerence in the intensity between the sample incubated with only 6 kDa CM, at 4 and
37 ◦C.
Figure 3.37: The histogram represents the ﬂuorescent intensity of the CRL 2429 cells pre-
incubated with the endocytosis inhibitor dynasore at 37◦C and sodium azide at 4 and 37◦C
for 30 min. The histogram is obtained from the cells seen outlined in ﬁgure 3.35. Each sample
has been illustrated with its own colour.
The results observed in ﬁgure 3.37 now show a signiﬁcant diﬀerence in ﬂuorescent intensity,
which might be caused by the high concentration of 1 mg/mL of 6 kDa CM. The cells may
have been saturated by the micelles, and will therefore not show any indications of hindered
endocytosis. As a result of this observation, the concentration was lowered to 0.5 mg/mL for
the experiments performed on the cell line U87.
In ﬁgure 3.38 the ﬂuorescent intensity of the U87 cells is illustrated, in relation to the counted
cells. From ﬁgure 3.38 a more deﬁned diﬀerence in ﬂuorescent intensity is seen. The cells
incubated at 4◦C are seen to have a lower intensity than the cells incubated at 37◦C. The
sodium azide does not express an inﬂuence on the cells. The cells incubated with dynasore
shows the large change in intensity, and the control sample has a lower intensity than the
samples incubated with curcumin.
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Figure 3.38: The histogram represents the ﬂuorescent intensity of the U87 cells pre-incubated
with the endocytosis inhibitor dynasore at 37◦C and sodium azide at 4 and 37◦C for 30 min.
The histogram is obtained from the cells seen outlined in ﬁgure 3.36. Each sample has been
illustrated with their own colour.
From the results seen in ﬁgure 3.38 a minimal diﬀerence in the ﬂuorescent intensity between
the samples incubated at 4 and 37◦C is seen. The sodium azide shows no signiﬁcantly inﬂuence
on the samples, when comparing to the samples incubated only with 6 kDa CM. Theoretically,
sodium azide is an inhibitor for oxidative phosphorylation - metabolic pathways to which cells use
enzymes to realise energy to form ATP. By hindering oxidative phosphorylation, sodium azide
is hindering the ATP syntheses in the cells and thereby inhibiting endocytosis mechanisms.
Therefore, an obvious diﬀerence in ﬂuorescent intensity was expected between the samples
incubated with 6 kDa CM and the sample pre-incubated with sodium azide. The same goes for
the minimal diﬀerence seen between 4 and 37 ◦C. By lowering the temperature, the process of
oxidative phosphorylation is slowed down due to the enzymes activity, which is slower at lower
temperatures, making the entire process of ATP syntheses slower, and with it the endocytosis
mechanisms. A reason for the minimal change in intensity observed between 4 and 37◦C, might
possibly be caused by a minimal change in temperature. To obtain a temperature of 4◦C the
culture ﬂask was placed in a refrigerator; after obtaining 100 % conﬂuence, the temperature of
the ﬂask were not checked before removing the growth medium and adding 3 ml of uncooled
0.01% sodium azide solution. By replacing half of the ﬂasks volume with uncooled solution,
the temperature might not have remained at 4◦C. By adding an additional 3 mL of uncooled 6
kDa CM solution after 30 min, the temperature will be changed again and might not reach a
temperature of 4◦C.
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When comparing the diﬀerence between 4 and 37◦C in ﬁgures 3.37 and 3.38, a large diﬀerence
is seen between the ﬁgures. Figure 3.37 show no sign of being inﬂuence by the temperature ,
where a more deﬁned diﬀerence is seen in ﬁgure 3.38; here the culture ﬂask was placed in the
refrigerator some time before adding solution, to obtain the equilibrated temperature. The
intensity diﬀerences are however still lower than expected. A more precise approach is therefore
needed, to maintain the temperature at 4◦C in the culture ﬂask and have the same temperature
for the solutions added to the ﬂask.
The largest diﬀerence in intensity is seen for dynasore at 37◦ incubated with U87 cells. This
result implies that dynasore inhibits the uptake of 6 kDa CM and that the U87 cells use dynamin
dependent endocytosis, which includes Clathrin-dependent endocytosis.
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It has been shown to be possible to synthesise small polymeric micelles of PVP polymer. Three
diﬀerent variations of PVP polymeric micelles were synthesised using curcumin, chloroform and 1
and 6 kDa PVP polymers. From studies of the micelles, using NanoSight and a multimode AFM,
their sizes where determined. The synthesis resulted in 1 and 6 kDa curcumin micelles, with
diameters of 80 nm and 142 nm respectively and empty micelles with diameters of 41 nm. The
PVP polymers size and the solvents curcumin and chloroform showed to have important inﬂuence
on the micelles size. The empty micelles synthesised using chloroform and 6 kDa polymer where 4
times smaller than the 6 kDa curcumin micelles and unstable. The use of chloroform contributed
to unstable empty micelles, because of the minimal hydrophobic interactions at core. Where the
curcumin loaded micelles have stronger hydrophobic interactions, attributed to curcumin. The
lyophilised powders texture also showed to be inﬂuenced by the polymer size. The texture of 1
kDa curcumin micelles was ﬂakier compared to the 6 kDa micelles; they were more smooth and
uniformly structured, which also showed to inﬂuence their ability to dissolve. The Nanosight
results showed that proper preparations of the micelles was necessary, in order to remove remains
of curcumin, polymer and micelle aggregates. From the AFM images it was concluded that the
curcumin micelles and empty micelles appeared to have diﬀerent surface charges. The empty
micelles were positively charged and collapsed on the freshly cleaved mica substrates, while
the curcumin micelles were negatively charged and collapsed on the APTMS modiﬁed mica
substrate.
The drug delivery application of the micelles was studied using optical ﬂuorescent microscopy,
to determine the cellular uptake of curcumin and overcome curcumins poor solubility. The results
showed that the polymeric micelles enhance the cellular uptake of curcumin, compared to free
curcumin, making curcumin micelles a promising formulation of curcumin to overcome the poor
solubility. Furthermore, the micelles pathways into the cells lines were studied by inhibiting the
endocytosis mechanisms, by treating the cells with the endocytic inhibitor dynasore and receptor
endocytosis inhibitor worthmaninn. For both cell lines, the inhibitors showed no variations
in ﬂuorescent intensity of curcumin uptake in the cells. Additionally, investigation into the
endocytosis mechanisms was conducted through the use of ﬂow cytometric analysis. The 6 kDa
curcumin micelles were incubated with sodium azide at 4 and 37◦C, to hinder ATP synthesis,
and thereby some of the endocytosis mechanisms. The results were inconclusive; only a small
variation was observed between 4 and 37◦C for cell line Glioblastoma (U87).
The cytotoxicity of the micelles was studied using a cytotoxicity assay, through a mortality
%. The results showed a high cytotoxic activity for both 1 and 6 kDa curcumin micelles over
a range of concentrations in both cell lines, compared to free curcumin. The high cytotoxic
activity for the micelles in ﬁbroblast cells is not ideal, but 6 kDa curcumin micelles showed a
lower activity than 1 kDa curcumin micelles, thereby making them more favourable, since they
had the highest cytotoxic activity in glioblastoma cells, inhibiting their growth more. Empty
micelles cytotoxic activity was also studied, to determine the cytotoxic activity of the PVP
polymer. For glioblastoma cells, the mortality was almost 100%, whereas ﬁbroblast cells showed
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A. AFM images for statistics
A representation of the 6 kDa CM AFM images used for section 3.1.4. In ﬁgure A.1 the ﬁrst six





Figure A.1: The AFM images used for height and radius distribution analysis. The AFM
images represents 6 kDa CM treated with ultrasound, which have been drop deposited on a
freshly cleaved mica substrate, see section 2.2.3.1.
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A. AFM images for statistics
In ﬁgure A.2 the last four AFM images are seen. All the images are from the same sample,
but from diﬀerent places on its surface.
(a) (b)
(c) (d)
Figure A.2: The AFM images used for height and radius distribution analysis. The AFM
images represents 6 kDa CM treated with ultrasound, which have been drop deposited on a
freshly cleaved mica substrate, see section 2.2.3.1.
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B. Light micro-graphs
From each cytotoxicity assay produced, have there been taking light micro-graphs from before
and after 24 h incubation with 1 kDa CM, 6 kDa CM and 6 kDa empty micelles. This chapter
represent some of the micro-graphs, two images for each point seen in the cytotoxicity graph
3.27 in section 3.3, one for before and after incubation. The remaining light micro-graphs can
be found on the attached CD.
The micro-graph images in ﬁgure B.2 represent the points for 1 kDa CM.
(a) (b)
(c) (d)
Figure B.1: The 1 kDa CM curve in ﬁgure 3.27. (a) and (c) represent the light micro-graphs





Figure B.2: The 1 kDa CM curve in ﬁgure 3.27. (a) and (c) represent the light micro-graphs
before incubation with 1 kDa CM, while (b) and (d)represent after.




Figure B.3: The 6 kDa CM curve in ﬁgure 3.27. (a) and (c) represent the light micro-graphs
before incubation with 6 kDa CM, while (b) and (d) represent after.
(a) (b)
(c) (d)
Figure B.4: The 6 kDa CM curve in ﬁgure 3.27. (a) and (c) represent the light micro-graphs
before incubation with 6 kDa CM, while (b) and (d) represent after.
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B. Light micro-graphs
The micro-graph images in ﬁgure B.5 represent the points for free curcumin.
(a) (b)
Figure B.5: The free curcumin point in ﬁgure 3.27. (a) represent the light micro-graphs
before incubation with free curcumin, while (b) represent after.
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